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ABSTRACT OF DISSERTATION

THE ONCOGENIC ROLE OF THE PROTEIN TYROSINE PHOSPHATASE 4A3
(PTP4A3 OR PRL-3) IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive blood cancer.
There are no immunotherapies and few molecularly targeted therapeutics available for the
treatment of this malignancy. The identification and characterization of genes and
pathways that drive T-ALL progression is critical for the development of new therapies for
T-ALL. The protein tyrosine phosphatase PTP4A3, also known as PRL-3, has been
extensively reported to play a causative role in numerous cancers, including several types
of blood malignancies. However, its role in T-ALL is not well defined.
Here, we determined that the PRL-3 plays a critical role in T-ALL initiation and
progression by promoting leukemia cell migration. PRL-3 is highly expressed in patient TALL samples at both mRNA and protein levels compared to normal lymphocytes. Knockdown of PRL-3 expression using short-hairpin RNA (shRNA) in human T-ALL cell lines
significantly impeded T-ALL cell migration capacity in vitro and reduced their ability to
engraft and proliferate in xenograft mouse models. Additionally, PRL-3 over-expression
in a Myc-induced zebrafish T-ALL model significantly accelerated disease onset and
shortened the time needed for cells to enter blood circulation. Reverse phase protein array
(RPPA) and gene set enrichment analysis (GSEA) revealed that the SRC signaling pathway
is affected by PRL-3. Immunoblot analyses validated that manipulation of PRL-3
expression in T-ALL cells affected the SRC signaling pathway, which is directly involved
in cell migration, although SRC was not a direct substrate of PRL-3. More importantly, TALL cell growth and migration was inhibited by small molecule inhibition of PRL-3,
suggesting that PRL-3 has potential as a therapeutic target in T-ALL.
Finally, we identified a pool of PRL-3 interacting proteins in T-ALL using BioIDbased proximal labeling approach. Co-immunoprecipitation assays were used to validate a
number of direct interacting partners of PRL-3, including LCK and CD3.
Taken together, our study identifies PRL-3 as an oncogenic driver in T-ALL both
in vitro and in vivo and provides a strong rationale for targeted therapies that interfere with
PRL-3 function. We also identified PRL-3 interactomes in T-ALL, which lays foundation
for future PRL-3 substrates study.
KEYWORDS: PRL3, T-ALL, Zebrafish, Migration, BioID2, Proximal-labeling
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CHAPTER 1.
1.1

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Introduction of T-cell Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia, also known as ALL, is a type of blood cancer in
which the bone marrow produces malignant and abnormal lymphocytes and fails to make
enough normal blood cells, leading to common symptoms such as fever, infection,
bruising, and bleeding. ALL is the most prevalent cancer among children, accounting for
20% of all cancers diagnosed in people aged <20 years. There are >3,000 new cases each
year in the United States. The overall incidence of pediatric ALL was 3.4 cases per
100,000/year from 2001–2014 with the highest incidence peak in children aged 1–4 years
(7.5/100,000)1. ALL also is one of the leading causes of death from cancer for children
younger than 20 years old2. In adults, ALL is the second most common acute leukemia,
with ~ 1300 new cases in the year 2016 in the United States1.
Despite the great success achieved in the treatment of ALL in the last 5 decades,
reflected by the enormous increase in survival rate, from less than 10% in the 1960s to
about 90% today, there are still challenges with its treatment. One challenge comes from
the short-and long-term toxicities due to the intensive chemotherapies. A study published
in 2008 following 4,151 pediatric ALL survivors demonstrated that 65% of them suffered
from at least one chronic condition and 21% reported severe medical conditions including
death, even 25 years after diagnosis3. Those medical conditions include long-term
neurocognitive deficits, neurologic dysfunction (stroke and peripheral neuropathies),
neuroendocrine dysfunction (growth hormone deficiency and precocious puberty),
metabolic abnormalities (obesity and metabolic syndrome), bone toxicity (osteonecrosis
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and bone mineral density deficits), and cardiac damage. Survivors of ALL treated with
cranial radiation therapy showed a highest risk for neurocognitive impairment4.
Another main clinical challenge for ALL is relapse, which remains a major source
of childhood cancer-associated mortality. A study following patients between 1988-2002
showed that 20.5% of pediatric ALL patients experienced relapse. The 5-year survival rate
after relapse is between 24.1% and 58.7%, depending on the site of relapse5.
ALL arises from two different types of lymphocyte precursors, T and B lymphocyte
precursors, and is correspondingly divided into two subtypes, T-ALL and B-ALL. T-ALL
is less common than B-ALL, only accounting for about 15% of all pediatric ALL cases and
25% of adult ALL cases5. However, T-ALL is a more aggressive subtype compared with
B-ALL, reflected by a significantly lower 5-year survival rate, 81.6% compared with
91.1% for B-ALL6.
1.2
1.2.1

Current Approaches and Challenges for T-ALL
Current Approaches for T-ALL Treatment

Currently, the main treatment of ALL is typically using intensive multi-drug
regimens, which typically includes 3 phases and lasts 2 to 3 years: induction therapy,
consolidation (intensification) therapy and maintenance therapy. There are 8 main
categories of antineoplastic agents used for childhood ALL (Table 1).
The goal of induction therapy, which normally lasts 4-6 weeks, is to attain a
remission where leukemia cannot be detected and no more symptoms in patients. The
chemotherapy drugs used in induction therapy is a cocktail consisting of glucocorticoids,
vincristine, L-asparaginase, and the optional use of anthracycline class according to the
risk stratification. Features including initial white blood cell (WBC) count, age,
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cytogenetics and ploidy, immunologic subtype, rapid and degree of cytoreduction are
used to stratify ALL patients into 3 groups, standard, intermediate or high risk. Almost all
patients can attain remission after induction phase, however, relapse is prevalent without
intensification therapy2,7.
The consolidation (intensification) phase, as its name suggests, is to consolidate
remission and also prevent spreading of leukemia to the central nervous system. The
consolidation phase lasts 6 to 8 months and often uses more intensive chemotherapy
combinations. The drugs used in this phase include methotrexate, a glucocorticoid,
vincristine, L-asparaginase, anthracycline class, 6-mercaptopurine (6-MP), etoposide,
cyclophosphamide, and cytarabine, but regimens vary among cancer centers 2,7.
Maintenance therapy is prolonged, lasting 18 to 30 months. Daily 6mercaptopurine (6-MP) and weekly methotrexate, often along with vincristine and a
steroid, is generally used in this phase2,7.
1.2.2

Challenges for T-ALL

T-ALL is a high-risk subgroup of pediatric ALL compared to B-ALL, and T-ALL
patients are typically classified into high-risk arms of risk-stratified regimens and are
subjected to more intensive treatment but still have higher risk of induction failure and
early relapse, compared to B-ALL patient8,9. A study followed 1,041 patients with
induction failure out of 44,017 patients and identified that the 10-year survival rate was
only ~28% for T-ALL patients compared with 41% for B-ALL6. Adult T-ALL has only
about 50% survival at 5 years1, which is comparable to adult B-ALL4. Central nerve system
(CNS) involvement, a major clinical problem of ALL, is also higher in T-ALL patients
compared with B-ALL4.The patients with CNS involvement require pre-emptive CNS-
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directed intrathecal chemotherapy and cranial radiation therapy. Meanwhile, the current
intensive multi-chemo regimens are non-targeted, often causing short- and longer-term
toxicities.
The prognosis of T-ALL relapsed patients is dismal. Only 23.0% of T-ALL relapse
patients achieved 5-year survival, significantly lower compared with that of B-ALL relapse
patients5. A major reason for this is that the development of new treatments for relapsed TALL lags behind that for relapsed B-ALL, which has benefited from several new targeted
therapy drugs, including imatinib10, inotuzumab ozogamicin11, blinatumomab11, and CART Cell therapy12. The only agent FDA-approved specifically for relapsed T-ALL is
nelarabine, which is a purine nucleoside analog and was approved in 2005. Several Phase
II studies using nelarabine as the single agent to teat pediatric T-ALL patients only
achieved short complete remission, between 31%-47%. Neurotoxicity of nelarabine was
also observed in clinical trial, including seizures, neuropathy, and mental status changes4.
In conclusion, lack of less toxic, targeted therapies for T-ALL severely affects the
prognosis and quality of life of the long-term survivors, most of which are children. No
effective salvage treatment for relapsed T-ALL leads to dismal outcomes in these patients.
Therefore, novel therapies for T-ALL are critically needed. In order to develop more
effective drugs to improve the outcome of relapsed T-ALL patients and to identify targeted
therapies to reduce the toxicity of current chemo-regimens, we need to identify and
characterize new drivers of T-ALL initiation and progression.

4

1.2.3

Development of Targeted Therapies for T-ALL.

Recent close collaboration between clinical groups and research labs have
identified that one of the hallmarks of ALL is genetic alterations which drive the initiation
and progression of the disease1. Tremendous efforts are being put to characterize those
genetic alterations, which may help to identify risk stratification, refine treatment regimens,
and develop novel targeted therapies, thus ultimately improving patient prognosis.
The most common recurrent genetic alterations in T-ALL are chromosomal
rearrangements, which are detected in up to 70% of T-ALL cases and commonly involve
T-cell receptor (TCR) genes, including TRA and TRD at 14q11, TRB at 7q34 and TRG at
7p14. These rearrangements frequently dysregulate a number of transcription factors and
related genes, including MYC (MYC Proto-Oncogene), TAL1/2 (T-cell acute lymphocytic
leukemia protein 1/2), LYL1 (lymphoblastic leukemia derived sequence 1), BHLHB1 (basic
helix-loop-helix transcription factor B1), LMO1/2 (LIM-only domain proteins 1/2),
TLX1/3 (T cell leukemia homeobox 1/3), NOTCH1(Notch receptor 1), CCND2 (G1/Sspecific cyclin-D2), and LCK (lymphocyte-specific protein tyrosine kinase).These
transcription factors are commonly involved in normal haemetopoiesis, T-cell self-renewal
and development. Their dysregulation leads to leukemogenesis and T-cell malignancies2,9.
The rapid development of Next Generation Sequencing (NGS) allowed
identification of a large set of mutations in T-ALL, including NOTCH1, FBXW7 (Fbox/WD repeat-containing protein 7), CDKN2A/2B (cyclin-dependent kinase Inhibitor),
BCL11B (B-cell lymphoma/leukemia 11B), JAK1 (Janus kinase 1), PTPN2 (Tyrosineprotein phosphatase non-receptor type 2), IL7R (Interleukin-7 receptor) and PHF6 (plant
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homeodomain (PHD)-like finger). Among them, NOTCH1, FBXW7 and CDKN2A/2B are
the most prevalent sites of mutation.
1.2.3.1 Targeting NOTCH1 Signaling Pathway for T-ALL
NOTCH1 activating mutations occur in >50% of T-ALL cases and FBXW7
mutations account for 10% to 15% of T-ALL cases, representing the most frequent
oncogenic pathway across all subtypes of T-ALL3. NOTCH proteins, including NOTCH14, are a family of type-1 transmembrane proteins that regulate cell-to-cell communication.
NOTCH proteins play a major role in T-cell lineage commitment. NOTCH1 has a major
role in regulating different intrathymic T-cell development stages. NOTCH proteins must
to be cleaved upon activation. The first cleavage of Notch protein is processed by Furin
before it is expressed on the cell surface as a heterodimer. ADAM 10, a metalloprotease,
and γ-secretase carry out the additional two cleavages, which ultimately generate active
intracellular domain of NOTCH (NICD). NICD is a transcription factor that can translocate
into the nucleus and regulates differentiation and proliferation through the activation of
various target genes. FBXW7 is part of the E3 ubiquitin ligase complex and controls
proteasome-mediated degradation of various proteins including NOTCH. Therefore, both
NOTCH1 activating mutations and inactivating mutations of FBXW7 lead to stabilization
of NICD in the nucleus, resulting in activation of oncogenic NOTCH1 signaling13,14.
As NOTCH1 hyper-activation is prevalent in T-ALL, great efforts have been put to
investigate the efficacy of anti-NOTCH1 antibody and γ-secretase inhibitors (GSIs) that
block NOTCH1 activation in the treatment of T-ALL. The anti-leukemic effects of antiNOTCH1 antibody have been demonstrated both in vitro and in vivo against T-ALL cell
lines, and also in xenotransplantation of primary T-ALL patient samples15,16. For example,
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anti-NOTCH1 monoclonal antibody significantly delayed xenotransplantation of T-ALL
patient samples harboring NOTHC1 mutations, where the anti-tumor effects came from
increased apoptosis, decreased proliferation and altered cell metabolism. Interestingly,
incorporation of dexamethasone significantly enhanced efficacy of anti-NOTCH1
monoclonal antibody therapy16.
Another strategy of inhibiting aberrant NOTCH1 signaling for the treatment of
leukemia is to use γ-secretase inhibitors (GSIs). Both in vitro and in vivo pre-clinical
studies have demonstrated anti-leukemic effects of GSIs17–21. GSIs treatment resulted in
G1 cell cycle arrest, increased apoptosis, decreased cell size and leukemic-initiating cell
activity. However, phase I clinical trials showed very limited therapeutic activity to date.
In addition, there are severe gastrointestinal toxicities of GSIs observed in the clinical trials,
which also restricts the clinical application of GSIs22,23.
1.2.3.2 Targeting Increased Kinase Activity for T-ALL
Although CDKN2A/2B is one of the two mutations present in >50% T-ALL except
NOTCH24, it is challenging to target it for T-ALL treatment. CDKN2A/2B encode the
INK4/ARF (Inhibitors of CDK4) family of tumor suppressors and cell-cycle regulators and
it is difficult to restore the activity of a deleted tumor suppressor gene.
Another aberrant phenotype in a subset of T-ALL that can be harnessed to develop
targeted therapies is increased kinase activity, including PI3K/PTEN/AKT pathway, ABL1
and JAT/STAT pathway. Mutation of PI3K/PTEN/AKT pathway was detected in ~50% of
pediatric T-ALL25. Phase I clinical trial of buparlisib, a pan-class I PI3K inhibitor, has been
finished and showed only moderate efficacy in advanced leukemia. Another PI3K
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inhibitor, dactolisib, is currently under Phase I clinical trial for use in relapsed or refractory
acute luekmia25.
NUP214 encodes nucleoporin 214, a protein required for cell cycle and
nucleocytoplasmic transport. ABL1 is a proto-oncogene encoding a protein tyrosine kinase
ABL1, which is involved in process of cell differentiation, division, and adhesion. The
fusion of NUP214 to ABL1 cannot activate the ABL1 kinase26. While episomal
amplification of NUP214-ABL1 resulted in oncogenic hyperactivation of ABL1. The
NUP214-ABL1 fusion transcript has been detected in a subset of T-ALL patients, varying
in the range of between 5.8% to 10%27. Preclinical studies showed that kinase inhibitors,
including imatinib, nilotinib, and dasatinib, were effective against NUP214-ABL1 positive
cell lines or mouse xenograft models. There are also case reports of NUP214-ABL1 positive
T-ALL patients responding to imatinib/dasatinib treatment28,29. Further evaluation of ABL
kinase inhibitors against a larger cohort of NUP214-ABL1 positive T-ALL patients is
needed.
JAK/STAT inhibition may also have therapeutic potential for T-ALL. The
activating mutations in JAK/STAT pathway, including mutations in IL7/IL7R, JAK1/3,
and/or STAT5 are detected in 20% to 30% T-ALL cases24. JAK1/2 inhibitor ruxolitinib
showed efficacy against T-ALL patient-derived murine xenograft models. Surprisingly, the
efficacy of ruxolitinib is not dependent on JAK/STAT pathway mutations30. Addition of
ruxolitinib or removing IL7 to inhibit JAK/STAT pathway overcame glucocorticoid
resistance in a subset of T-ALL in patient derived xenograft models31.
Although great efforts have been put in developing targeted therapies for T-ALL,
it still lags behind that of B-ALL and other types of leukemias. T-ALL patient has not
8

received benefits from the above discussed target therapies. The identification and
characterization of new drivers for T-ALL is critically needed for this purpose. Contrarily
to the protein tyrosine kinases, which are the most successful drug target and achieved
great clinical success, protein tyrosine phosphatases are underexplored as cancer
therapeutic targets. The past two decades study about protein tyrosine phosphatases
demonstrated potential of them as cancer targets and are receiving arising attention32,33.
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Table 1 Chemotherapeutic Drugs for Childhood Leukemia
Drug Class
Drugs
Dexamethasone
Prednisolone
Glucocorticoids
Methylprednisolone
Prednisone
Vincristine Sulfate
Vinca alkaloids
Vincristine Sulfate Liposome
Calaspargase pegol
Asparaginase Erwinia Dhrysanthemi
L-Asparaginase
Erwinase
Pegaspargase
Daunorubicin
Anthracycline
Doxorubicin
Idarubicin
Alkylating agents
Cyclophosphamide
Methotrexate

methotrexate

Purine Analogs
Pyrimidine Analog

6-thioguanine
6-mercaptopurine
Cytarabine

Epipodophyllotoxins

Etoposide

Adapted from Table 7.14

Mechanisms

Part in protocol

Apoptosis by binding to intracellular
steroid receptors

Throughout

Disruption of mitotic spindle

Throughout

Depletion of L-asparagine

Induction and
intensification

DNA intercalation Inhibition of topoisomerase II function

Induction and
intensification

Inter-strand DNA cross-links

Intensification
Maintenance CNSdirected therapy

Anti-folate
Inhibition of DNA synthesis

Maintenance

Inhibition of DNA synthesis
Interferes with topo II re-ligation of
double-stranded DNA breaks

Intensification
Intensification

CHAPTER 2.
2.1

PRL-3 IS AN ONCOGENIC PHOSPHATASE

Phosphatases are Underexplored Drug Targets

Protein tyrosine phosphatases (PTPs) are a large family of enzymes that catalyze
the removal of phosphate groups that are attached to tyrosine residues on substrates. Protein
tyrosine kinases (PTKs), on the contrary, are the enzymes that transfer a phosphate group
to the tyrosine residue on corresponding substrates. PTPs cooperate with PTKs to precisely
maintain appropriate protein phosphorylation and have important roles in modulating the
strength and duration of signaling events, which is critical for normal cellular functions,
including cell survival, apoptosis, proliferation, migration as well as differentiation32.
The aberrant phosphorylation of proteins is implicated in many human diseases,
including cancer, inflammatory diseases, diabetes/obesity, central nervous system (CNS)
disorders, and cardiovascular diseases32. Since over-activation of PTKs is a common
feature of many types of cancer, PTKs are one of the most intensively explored drug targets
for cancer treatment. As a result, several PTK inhibitors have achieved clinical success and
become the standard of care in several types of cancer, including afatinib for non-smallcell lung cancer34 and imatinib for chronic myeloid leukemia35.
However, until recently, PTPs have not received similar attention as therapeutic
targets, primarily due to misconceptions that phosphatases are only tumor suppressors or
that they lack regulatory roles in disease32,33. Nonetheless, accumulating evidence has
shown that phosphatases are suitable therapeutic targets in cancer. For example, Protein
Tyrosine Phosphatase 1B (PTP1B) is reported to play a tumor-promoting role in prostate
and colorectal cancer36, and high PTP1B expression is associated with poor prognosis in
colorectal cancer patients36,37. Additionally, protein tyrosine phosphatase SHP2 (Src
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homology region 2 (SH2)-containing protein tyrosine phosphatase 2) increases tumor
progression and maintains tumor-initiating cells in breast cancer38,39. To date, more than
30 potential oncogenic phosphatases have been identified, and are currently being explored
as drug targets in cancer therapy. Consequently, the interest in exploring phosphatases as
drug targets to treat cancer has risen sharply in the last decade.
2.2

Introduction of PRLs

PRLs (Phosphatase of Regenerating Liver), also known as the Protein Tyrosine
Phosphatase 4A (PTP4A) family, are dual-specificity phosphatases, which can act on
tyrosine residues and serine/threonine residues to remove phosphate40. PRL-1 was the first
identified PRL and discovered in 1991 as one of the immediate-early genes up-regulated
in regenerating rat liver after partial hepatectomy41. Later, the sequence analysis of PRL-1
identified a PTP signature motif, Valine-Histidine-Cysteine-(any amino acid)5-Arginine
(VHC(X)5R), but with no homology to other PTPs outside this signature sequence. In vitro
phosphatase assays using a generic DiFMUP substrate demonstrated that PRL-1 had
phosphatase activity. Therefore, PRL-1 emerged the first in a new class of PTPs42.
Later, PRL-2 and PRL-3 were identified based on a sequence homology search in
the Murine Expressed Sequence Tags database43. In humans, PRL-1 and PRL-2 are most
similar in amino sequence, sharing 87% homology, while PRL-1 and PRL-3 exhibit 79%
homology, and PRL-2 and PRL-3 are 76% homologous (Figure 1)44,45.
The genes that encode PRL-1, PRL-2, and PRL-3 are found on chromosome 6q12,
1p35, and 8q24.3, respectively. PRL-1 and PRL-2 mRNA expression was ubiquitously
detected across almost all normal human tissues and major organ systems46, while PRL-3
expression was detected primarily in the heart, skeletal muscle, vasculature, and the brain43.
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PRL proteins have a small molecular weight, at 22kDa, with 173 amino acids in
PRL-1 and PRL-3, and 167 amino acids in PRL-244. Sequence alignment of PRL-1, PRL2, and PRL-3 shows that they all carry the conserved catalytic PTP motif
VHC (X)5R, also known as a P-loop, a WPFDD (Tryptophan-Proline-PhenylalanineAspartate-Aspartate) loop, polybasic region, and CAAX (where C represents Cysteine, A
represents aliphatic amino acid and X refers to any amino acid) prenylation motif (Figure
1), the functions of which are highlighted below.
Similar to other PTPs, the cysteine residue in the P-loop (Cys104 in PRL-1 and
PRL-3 or Cys101 in PRL-2) acts as a nucleophile during phosphorylation, forming a
thiophosphoryl enzyme intermediate (Figure 2). C104S mutation was shown to abolish
PRL enzymatic activity in vitro

47,48and

its metastatic activity in a xenograft mice

model49,50. The arginine residue in the P-loop (Arg110 in PRL-1 and PRL-3 or Arg107 in
PRL-2) facilitates substrate binding by interacting with the phospho-tyrosine in substrates.
An R110A mutation in PRL-3 completely abolished its phosphatase activity in vitro48. The
second aspartate residue in the WPFDD loop (Asp72 in PRL-1 and PRL-3 or Asp69 in
PRL-2) acts as a general acid by donating a proton to the substrate in the first step and a
general base by activating a water molecule in the second step, promoting formation and
hydrolysis of the enzyme intermediate (Figure 2). D72A mutation has been reported to
decrease PRL catalytic activity49,51. Therefore, both the P-loop and WPFDD loop are
critical for PRL phosphatase activity.
The CAAX motif, also known as a prenylation motif, at C-terminus of PRLs is
unique to PRLs and not found in other PTPs. This feature is important for PRL
subcellularlocalization51. The polybasic region preceding CAAX motif (between residues
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151 and 161 in PRL-1 and PRL-3 or between 148 and 158 in PRL-2) facilitates PRLs
binding to the membrane by interacting with negatively charged phospholipids in the
membrane40,52. Overexpressed N-terminal Myc-tagged PRL-1, PRL-2, and PRL-3 in CHO
cells were all shown to localize on the plasma membrane and early endosome using
immunofluorescent microscopy and electron microscope immunogold labeling. Inhibition
of prenylation of PRL-1, PRL-2, and PRL-3 using selective farnesyltransferase inhibitor
FTT-277 led to re-distribution of all the PRLs into the nucleus. Similarly, the truncated
PRL-2 without the CAAX motif was localized in the nucleus. The re-distribution of PRLs
between plasma membrane and nucleus may play a role in functional regulation of PRLs51.
The alanine residue following the arginine residue in the P-loop also differentiates
PRLs from other PTPs. Serine or threonine, which is believed to play an important role in
the hydrolysis of the phosphoenzyme intermediate, occupies this position in most PTPs.
Consistently, a mutation of PRL-1 that replaces this alanine with a serine (A111S) showed
increased activity toward synthetic substrate52. The presence of alanine instead of
serine/threonine in PRLs may therefore contribute partially to the low phosphatase activity
of PRLs in vitro. The residues in P-loop of PRL-3, Val105-Ala-Gly-Leu-Gly109, is highly
hydrophobic compared with other phosphatases47, which suggests different substrate
selectivity. This feature implies the possibility of developing hydrophobic high affinity
competitive PRL inhibitors with better cell permeability, as other PTP competitive
inhibitors are more likely to be highly charged due to charged active site.
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2.3
2.3.1

PRL-3 and Cancer
Oncogenic Role of PRL-3

PRLs are largely considered oncogenic phosphatases that play critical roles in
tumor progression and metastasis across a variety of human cancers. PRL-3 is the best
studied PRL and extensively reported as a biomarker of tumor progression and metastasis.
PRL-3 expression was elevated in tumor tissues, compared with healthy tissues, or in
advanced versus early stage tumors, spanning colorectal53,54, breast55,56, gastric57,
ovarian58, liver59, prostate60, lung61 cancers, AML (acute myeloid leukemia)62,63 and BALL ( B-cell acute lymphoblastic leukemia)64. Importantly, high PRL-3 expression was
often correlated with poor prognosis in patients with colon65, breast55,56,66, gastric67,68,
liver59, lung61, ovarian cancers69 and AML62, which suggests a causative role for PRL-3 in
cancer progression. A direct contributing role for PRL-3 in cancer has been demonstrated
by over-expression and knockdown of PRL-3 in normal or cancer cell lines. For example,
human cell lines transfected with PRL-3, spanning human melanoma, breast, lung, and
colorectal cancer, exhibited increased oncogenic properties compared to control, including
increased motility, migration, invasion, and proliferation in vitro. PRL-3 expression
significantly enhanced tumor progression and metastasis after transplantation of the
transfected cells in mice49. Conversely, PRL-3 knock-down led to decreased cell
proliferation, migration, and invasion of melanoma, gastric, ovarian, lung cancer cell line
in vitro and inhibited primary tumor proliferation and metastasis in mouse cancer or
xenograft models70.
The role of PRL-3 in cancer is further demonstrated in a Prl-3 knockout mouse
model71. In this model, Prl-3 deletion protected mice from developing colon cancer
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induced by azoxymethane and dextran sodium sulfate. They also observed increased Prl-3
mRNA expression in the colon tissues of Prl-3 wildtype mice as early as 8 hours after
azoxymethane treatment, suggesting a correlation of Prl-3 with tumor initiation.
Consistent with the findings in PRL-3 knockout mice, there is additional evidence
that PRL-3 may also play an important role in the tumor angiogenesis. For example, PRL3 mRNA was detected in endothelial cells within colon cancer metastasis72and was
increased 6-fold in breast tumor endothelium compared to surrounding epithelial cells73.
Overexpression of PRL-3 in human microvascular endothelial cells (HMVEC) in vitro
enhanced endothelial tube formation74 and endothelial cell migration73. Additionally, PRL3 knock-out in mice led to decreased micro-vessel density in colon tumor tissues compared
with wild type controls. Furthermore, vascular cells isolated from PRL-3-null mice were
less invasive and migratory in vitro, compared with wild type cells. Further studies are
needed to definitively link PRL-3 to angiogenesis in the cancer setting, and the role of
PRL-3 in other migratory cells within the tumor microenvironment, such as fibroblasts and
immune cells, remains to be defined.
In conclusion, these studies demonstrated that elevated PRL-3 expression is a
common feature across various cancer types, suggesting that PRL-3 can serve as a
biomarker of tumor progression and a potential predictor of patient prognosis. In addition,
the causative role of PRL-3 in tumor progression implies that PRL-3 holds the potential for
cancer treatment.
2.3.2

PRL-3 Substrates and Signaling Pathways Mediated by PRL-3

The substrates study of phosphatase is generally challenging as the interaction
between phosphatase and its substrate is weak and transient, making isolation of the
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phosphatase-substrate complex difficult. This challenge is reflected by the fact that there
are only 336 protein substrates and 83 non-protein substrates identified for 241 human
phosphatases according to DEPOD database (http://depod.bioss.uni-freiburg.de/br_s.php)
as of February 22, 2020. In contrast, there are 10257 protein substrates for 518 protein
kinases according to the RegPhos (http://140.138.144.141/~RegPhos/index.php). It is
even more challenging to identify PRL substrates, as the catalytic pocket of PRLs are
shallower and wider compared to other PTPs51. Consequently, only Keratin 8 and integrin
β1 showed evidence as PRL-3 direct substrates. Nonetheless, a few PRL-3 interacting
proteins, not necessarily direct targets, have been reported (Table 2).
Keratin 8 has been reported as a PRL-3 substrate, which is identified by
differential phospho-protein examination using 2D-PAGE combined with MS approach
in SW480 colorectal cancer cells that overexpressed wild type or C104S mutant PRL-3.
Co-immunoprecipitation and co-localization assay validated that dephosphorylation of
keratin 8 at S73 and S431 by PRL-3 is a direct interaction. Importantly, IHC staining of
CRC patient samples showed that PRL-3 high expression associated with reduced
phosphorylation of keratin 8, particularly at the invasive front and in the liver
metastasis75. However, due to the limited samples examined, it is not known that whether
this correlation is prevalent or not. And how the dephosphorylation of keratin 8 regulated
by PRL-3 contributes to colorectal cancer is not studied.
Integrin β1, one member of integrin family and critical player in cell adhesion
regulation, is another reported PRL-3 substrate. Overexpression of PRL-3 in HEK293
(Human embryonic kidney 293) cells down regulated phosphorylation of integrin β1 while
knockdown of PRL-3 increased phosphorylation of integrin β176. Similar finding was
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identified by the same group in human colon cancer LoVo cells, which also showed that
PRL-3 is physically associated with integrin β1 in a co-IP assay, suggesting that integrin
β1 is a direct substrate of PRL-3. Importantly, the enhanced cell motility and invasion by
PRL-3 is abolished by depletion of integrin β1 in LoVo cells. In addition, PRL-3 mediated
metastasis of colon cancer in nude mice was also inhibited by knockdown of integrin β177.
The mechanistic study showed that PRL-3 overexpression activates ERK 1/2 while PRL3 knockdown inhibits ERK 1/2 pathway. However, the exact tyrosine residues in integrin
β1 that PRL-3 acts on was not reported in this study and how phosphorylation of integrin
β1 is connected to ERK ½ pathways needs further study76,77.
Besides keratin 8 and integrin β1, there are several other suggested PRL-3
substrates, but no strong evidence as PRL-3 direct substrates (Table 2). For example,
stathmin78, an important protein involved in the regulation of the microtube cytoskeleton
and CDH2279, one member of cadherin family, have been shown to be associated with
PRL-3 in multiple CRC (colorectal colon cancer) cell lines and /or primary CRC tissues
by Co-IP and co-localization assay. In addition, the expression of stathmin or CDH22 is
regulated by PRL-3. Similarly, Integrin α1 was identified as a PRL-3 interacting protein
using yeast two-hybrid system and validated by co-IP in COS-7 monkey fibroblast cells
that overexpress both PRL-3 and 76. However, the phosphorylation regulation of
stathmin, CDH22 or integrin α1 by PRL-3 was not reported, therefore whether stathmin,
CDH22 or integrin α1 are direct substrates of phosphatase PRL-3 needs further
investigation.
Ezrin, a member of ERM family (ezrin/radixin/moesin)80, elongation factor 281,
phosphoinositide PI (4,5) P2 and PI (3,4,5) P382 are also suggested PRL-3 substrates.
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There is evidence to show that PRL-3 regulates the phosphorylation of these suggested
substrates, however, there was insufficient evidence to conclude the direct interaction
between them and PRL-3.
CNNM, cyclin M family proteins and known as magnesium transporters, are
identified as PRL-3 interacting proteins. The reciprocal Co-IP experiments in COS-7 and
HEK293 cells demonstrated that PRL-3 is physically associated with CNNM1/2/3/4. The
binding of PRL-3 to CNNM blocks the efflux of Mg2+ and consequently increase
intracellular Mg2+concentration, which is reported to relate to tumorigenesis and tumor
progression83.The PRL-3-CNNM3 complex structure resolved by crystallography
provides molecular evidence for the interaction of PRL-3 and the CNNM family, which
showed that PRL-3 is a pseudophosphatase as PRL-3 does not alter the phosphorylation
of CNNM, though48.
In order to understand the molecular mechanisms of how PRL-3 contributes to
tumor initiation and progression, extensive studies have examined the signaling pathways
affected by PRL-3. An unbiased mass-spectrometry-based approach was used to examine
protein tyrosine phosphorylation related signaling networks affected by PRL-3
overexpression in Human Embryonic Kidney (HEK) cells, and identified an extensive
signal transduction network downstream of PDGF(α/β)-, Eph (A2/B3/B4)-, and Integrin
(β1/β5)-receptors, including SRC, Rho-family GTPase, PI3K/Akt, STAT and ERK
pathway activation84. These finding are corroborated in various cell models by different
labs (Table 3).
Rho family GTPases are a subfamily of the Ras superfamily and are key
regulators of tumor cell motility and invasion via regulation of the actin cytoskeleton.
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Overexpression of Rho family GTPases has been demonstrated in multiple cancer
types85.
Overexpression of PRL-3 in colorectal cancer cells activates RhoC86. Blocking
PRL-3 in A549 lung cancer cells with an anti-PRL-3 antibody inhibits RhoA/C activity,
leading to decreased cell migration and invasiveness61. PRL-3 physically associates with
Arf1 (ADP-ribosylation factor 1), another small GTPase, and overexpression of PRL-3 in
Hela cells activates Arf1, which is required for PRL-3 mediated cell migration87.
PTEN/PI3K/AKT is an important pathway involved in multiple biological
processes including cell proliferation, survival, apoptosis and metabolism.
Overexpression of PRL-3 in Hela and DLD-1 cancer cells reduce expression of PTEN, a
negative regulator of PI3K/AKT pathway, and consequently activates PI3K/AKT
pathway while overexpression of a phosphatase dead mutant PRL-3 C104S
overexpression did not88. The activation of the PI3K/AKT pathway promotes EMT
(epithelial-mesenchymal transition), reflected by up-regulation of mesenchymal markers,
such as fibronectin and Snail, and down-regulation of epithelial markers including Ecadherin, γ-catenin and integrin β3. Interestingly, a study using MEFs (mouse embryonic
fibroblasts) showed that PRL-3 overexpression induces cell cycle arrest via inhibition of
PI3K/AKT pathway, which is not recapitulated in RKO colon cancer and U2OS
osteosarcoma cells89.
Aberrant activation of Src, a non-receptor kinase, occurs in a large fraction of
cancers and plays a prominent role in cell migration and metastasis90. Ectopic expression
of PRL-3 in HEK293 activated the Src pathway, reflected by decreased phosphorylation
of Y527, which is an inhibitory phosphorylation site. However, Src was not a direct
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substrate of PRL-3, instead, decreased Y527 phosphorylation occurred via PRL-3
mediated down-regulation of Csk, which is a kinase responsible for Src Y527
phosphorylation. Activation of the Src pathway leads to downstream activation of
ERK1/2, STAT3, and p130Cas, which consequently promotes cell invasion, proliferation,
and transformation. In addition, Src activation and Csk down-regulation are more
significant in colon cancer cells that have higher PRL-3 expression, compared to lines
with lower PRL-391. A study in B-ALL (acute lymphoblastic leukemia) cells
demonstrated that PRL-3 knockdown inhibits Src pathway via decreasing
phosphorylation of Y416, an activating phosphorylation site in Src. Src activation,
together with FAK activation, regulates B-ALL cells adhesion and migration.
In conclusion, PRL-3 is involved in a wide range of signaling pathways, which
explains its oncogenic role, including cell migration, invasion, cell survival, apoptosis
and proliferation. However, since PRL-3 substrates are largely unknown, we do not know
what signaling pathways are directed regulated by PRL-3 and whether this regulation is
dependent on its phosphatase activity. And most of the studies of PRL-3 discussed here
were performed in solid tumors and there is no study to define its role in T-ALL, it would
be informative to examine the oncogenic role and substrate of PRL-3 in T-ALL.
2.4

Oncogenic PRL-1 and PRL-2

Similar to PRL-3, both PRL-1 and PRL-2 are reported to have oncogenic roles in
cancer, but these are less well defined. High PRL-1 expression was observed in cervical92,
gastric cancers93and intrahepatic cholangiocarcinoma94. PRL-1 expression was correlated
with poor patient prognosis in hepatocellular carcinoma95 and prostate cancer96. PRL-2
expression was significantly increased in breast cancer93 and hepatocellular carcinomas97.
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Inconsistently, in situ hybridization and immunohistochemistry showed that PRL-1
expression was lower in ovarian, breast, and lung cancers and PRL-2 was significantly
down-regulated in kidney carcinomas compared to normal tissue93. However, the number
of cases examined in this study was limited, and further research needed to validate the
expression level of PRL-1 and PRL-2 in these cancer types.
Studies of PRL-1 or PRL-2 over-expression or knockdown in cell lines show that
PRL1/2 may have similar functions as PRL-3. For example, PRL-1 overexpression in
Chinese Hamster Ovary (CHO) cells led to increased cell motility and invasiveness in vitro.
The injection of those cells in nude mice induced lung tumor and liver metastasis; similar
to the effects of PRL-3 overexpression in CHO cells98. The D27 hamster pancreatic ductal
epithelial cells that ectopically overexpress PRL-1 or PRL-2 showed loss of contact
inhibition in vitro and induced tumor growth in nude mice99. Different mouse mammary
tumor–derived cell lines that overexpress PRL-2 showed increased anchorage-independent
growth and cell migration. In addition, injection of DB-7 mammary cancer cells with PRL2 overexpression into the mouse mammary fat pad increase tumor growth100. Finally, PRL2 knock-down reduced the anchorage-independent growth and cell migration of human
metastatic MDA-MB-231 breast cancer cells and reduced the cell migration and invasion
of human A549 lung cancer cells, which can be rescued by co-transfecting an siRNA
resistant PRL-2.
2.5

Therapeutic Potential of PRL-3 in Cancer

As the contributing role of PRLs, especially PRL-3, in tumor progression and
metastases is now widely accepted, there has been great interest in developing specific PRL
inhibitors as novel anti-cancer reagents. However, the conservative active site of PRLs with
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other PTPs and the high percentage of identical primary sequence among PRLs present
obstacles for developing small molecules that specifically target the PRL44. Consequently,
the currently available PRL inhibitors have low selectivity, exhibiting inhibitory effects
against other PTPs or all three PRLs (Table 4). As several PTPs, such as PTEN, are well
known as tumor suppressors, it is critical to specifically target the oncogenic PRLs while
sparing the tumor suppressing PTPs. Table 4 describes the currently available PRL
inhibitors, which were identified or developed via high-throughput screening, virtual
screening and/or SAR studies, and natural product screening.
A high-throughput screen of the Roche chemical library for molecules that inhibit
PRL phosphatase activity against a peptide substrate identified thienopyridone, which
showed selectivity for PRLs over 11 other phosphatases, including tyrosine phosphatases
and dual-specificity phosphatases such as PTP1B, SHP2, and CD45101. Thienopyridone
was shown to significantly inhibit tumor cell anchorage-independent growth in soft agar
and migration and induce anoikis via induction of the p130Cas cleavage in a p53independent manner101. A structural-activity-relationship (SAR) study of thienopyridone
aiming to increase its stability and reduce its potential toxicity led to the development of
JMS-053 (iminothienopyridinedione 13), which is a photooxygenation product of
thienopyridone and showed a 10-fold increase in potency to inhibit PRLs compared to
thienopyridone102,103. JMS-053 is a reversible and noncompetitive inhibitor of PRL-3
when using the 6,8-difluoro-4-methyl-umbelliferyl phosphate (DiFMUP) substrate. The
specificity test of JMS-053 against a panel of 25 other phosphatases, including receptorlike PTPs, cytosolic PTPs, and dual specificity phosphatases, and 50 kinases showed that
it is highly specific for the PRL family. The anti-tumor activity of JMS-053 has been
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demonstrated in ovarian cancer in vitro and in vivo. JMS-053 rescued microvascular
barrier function of endothelia cells, which was dysregulated when exposed to vascular
endothelial growth factor or lipopolysaccharide. JMS-053 inhibited cell proliferation,
migration and spheroid growth of ovarian cancer cells. Importantly, JMS-053 exhibits antitumor activity on drug resistant ovarian cancer in a murine xenograft model at
concentration as low as 0.1μM. In addition, the anti-tumor activity of JMS-053 was
demonstrated on colon cancer and breast cancer cells in a three-dimensional spheroid
assay104.
While JMS-053 is the most potent and specific PRL inhibitor developed, neither
thienopyridone nor JMS-053 show specificity among the three PRLS. Although these
compounds may still be beneficial, since all PRLs appear to have oncogenic effects and it
may not be necessary to selectively target individual PRLs, until the normal functions of
PRLs are known, it may be difficult to bring these compounds to the clinic.
The small molecule PRL inhibitors that have been identified to date have no
selectivity for the different PRLs, which is likely due to the extremely high degree of
sequence identity among them. A different but promising strategy to specifically target
different PRLs is the use of antibodies although intracellular proteins are generally
considered not targetable by antibodies. This convention was challenged by a study where
PRL-1 and PRL-3 mouse or rabbit antibodies have been developed that can specifically
block the lung metastasis of xeno-transplanted breast cancer cell lines that overexpressing
PRL-1 or PRL-3, respectively105. The study also provides evidence that a fraction of human
breast cancer cells is able to take up antibodies, which is also significantly facilitated by
serum-starving. The anti-tumor effect of PRL antibodies is further validated by the study
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from the same group. A new generation of humanized PRL-3-zumab effectively inhibited
tumor burden in orthotopic mouse model of PRL-3-positive human and mouse liver cancer
cells and prolonged their survival. However, PRL-3-zumab did not affect cell growth of
PRL-3-positivel live cancer cells in vitro. The difference between in vitro an in vivo was
explained by that PRL-3-zumab treatment recruited B cells, NK cells and macrophages to
the tumor micro-environment for its anti-tumor activity106. In total, these efforts support
the concept that phosphatases are in fact druggable and suggest that PRL-3 is a feasible
therapeutic target in cancer.
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Figure 1. PRLs are Highly Homologous. The P-Loop and WPFDD Loop are critical to
phosphatase activity. The prenylation motif targets PRLs to the plasma membrane. The
polybasic region facilitates PRLs binding to the plasma membrane.
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Step 1

Step 2

Figure 2. Two-step Catalytic Mechanism of PTPs.
PRLs share a canonical two-step catalytic mechanism with other PTPs. In step one, the
thiolate anion of the Cysteine residue in the P-loop acts as a nucleophile, attacking the
phosphate group on the substrate then forming a thiophosphoryl enzyme intermediate,
and the second aspartate reside in the WPFDD loop acts as a general acid by donating a
proton to the leaving group in the substrate. In step two, the same aspartate residue acts as
a general base by activating a water molecule that can hydrolyze the enzyme-phosphate
complex and then release the phosphate.
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Table 2 PRL-3 Interacting Proteins
Interacting
Models
Outcome of Interaction
protein
SW480,
LoVo,
Decreased Stathmin protein expression but
Primary
Stathmin
its phosphorylation by PRL-3 was not
colorectal
studied.
tumor
Decreased CDH22 protein expression but
SW480,
CDH22
direct de-phosphorylation of CDH22 by
SW620
PRL-3 was not studied
Dephosphorylation of Integrin β1, direct deCOS-7
Integrin α1
phosphorylation of Integrin α1 by PRL-3
was not studied
Dephosphorylation of Elongation factor 2,
HTC116
exact residue was not determined and
Elongation factor 2
physical association with PRL-3 was not
determined
Dephosphorylation of Thr 567 of Ezrin but
HTC116
Ezrin
no evidence showing direct interaction with
PRL-3
Dephosphorylation of PI (4,5) P2 and
PI (3,4,5) P3,
PI (3,4,5) P3 by PRL-3 in vitro but no in vivo
/
PI (4,5) P2
evidence for PRL-3 lipid phosphatase
activity
COS-7
Inhibits Mg2+ efflux mediated by
CNNM4
HEK293
CNNM1/2/3/4

Approaches used

Ref.

Differential protein phosphorylation in
PRL-3 knockdown cells/Co-IP

78

Yeast two-hybrid system/ co-IP/Colocalization

79

Yeast two-hybrid system/co-IP

76

Differential protein phosphorylation in
PRL-3 overexpressing cells

81

Differential protein phosphorylation in
PRL-3 overexpressing or knockdown
cells/ in vitro de-phosphorylation assay

81

In vitro phosphatase activity assay

82

Co-IP and in vitro binding assay
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Table 3 Signaling Pathways Affected by PRL-3
Models
PRL-3 manipulation
SW480 (colorectal cancer cells)
overexpression
Blocking with anti-PRL-3
A549 (lung cancer cells)
antibody
Hela (cervical cancer cells)

29

Hela (cervical cancer cells)
DLD-1 (Colorectal cancer cells)
MEFs (mouse embryonic fibroblasts)
HEK 293(Human embryonic kidney
cells)
SW480 and 620 (colorectal cancer cells)
Reh and MHH-CALL-4
(preB-ALL cells)
MOLM-14 (AML cells)
SW480 (colorectal cancer cells)
HCT116 (colon cancer cells)

Altered signaling pathways
GTPase (RhoC)

Ref.

RhoA/C, ERK

61

Overexpression

Arf1(ADP-ribosylation factor 1),
integrin α5

87

Overexpression

PI3K-AKT, GSK 3β, EMT

88

Overexpression/knockdown

PI3K-AKT, p19Arf-p53-p21

89

overexpression

Src pathway, ER1/2K, STAT3, p130Cas.
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Src, FAK (focal adhesion kinase)

64

STAT3/5, apoptotic pathway
GSK 3β, β-catenin, Cadherin, EMT
P53

79

Knockdown
overexpression
Overexpression /knockdown
Overexpression/knockdown
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79
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Table 4 PRL inhibitors
Inhibitor

Pentamidine

30

Thienopyridone

Potency and Selectivity

Discovery

The clue comes from that
Similar activity against PRL1/2/3:
Pentamidine has similar antiIC50 < 0.277μg/ml using peptide
leishmania action as SSG,
substrate; also shows activity against
which has anti-cancer
other phosphatases
activity via inhibiting PTPs.

PRL1: IC50 = 173 nM
PRL2: IC50 = 277 nM
PRL3: IC50 = 128 nM
Shows selectivity over 11 other
PTPs (DiFMUP).

PRL1: IC50 = 50 nM
JMS-053
PRL2: IC50 = 53 nM
(Iminothienopyr
PRL3: IC50 = 18 nM
idinedione 13)
Minimal effect on PTP1B at 50 μM.

Cellular efficacy
Inhibits growth of five human
cancer cell lines with PRL
expression within the
concentration ranges 0.35μg/ml; inhibits growth of
WM9 human melanoma
tumors in nude mice and
results in tumor necrosis.

Induces p130Cas cleavage and
apoptosis in Hela and RKO
cells; inhibits anchorageindependent growth in RKO
and HT-29 cells; inhibits
HUVEC cells migration but
not proliferation.
Inhibits the proliferation,
Identified during the process spheroid viability, and
of SAR study of
migration of OvCa cells, and
thienopyridone to increase its also impedes the in
stability and reduce its
vivo growth of drug-resistant
potential toxicity.
OvCa in xenograft mouse
model
High-throughput screening
of the Roche chemical
library to search for
molecules that inhibits PRL
phosphatase activity using
peptide substrate.

Ref.

110

101

111

Table 4 PRL inhibitors (Continued)
Inhibitor
Potency and Selectivity

Rhodanine
and
its derivatives

31

CG-707 and
BR-1

Analog 3

Discovery

Cellular efficacy

Ref.

Inhibit human PRL3 activity with
IC50 range 0.9 ~ 9.5 μM; compound
5e is the most active one with IC50
0.9 μM against PRL3; not tested on
other PRLs and PTPs (DiFMUP).

Rhodanine skeleton was
identified by high throughput
screening of chemical library
of Korean Chemical Bank
and 14 derivatives were
synthesized for SAR study.

Compound 5e reduces
invasiveness of B16F10 cells in
vitro.
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Inhibit human PRL3 activity:
CG-707: IC50= 0.8 μM
BR-1: IC50=1.1 μM
Minimal effects on 9 other PTPs
(DiFMUP).
Suppress cancer cell migration:
CG-707: IC50= 5 μM
BR-1: IC50=7 μM

Inhibit the migration and
invasion of cancers that express
Using cell-based assay to
PRL3 without affecting
screen Rhodanine derivatives
proliferation; change the
expression of EMT markers.
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Inhibit human PRL3 activity PRL3:
IC50 = 31 μM
Shows acceptable selectivity against
PTP1B, TCPTP and VHR and no
selectivity against PRL1 and PRL2
(DiFMUP).

Ligand based virtual
screening of Zinc database
combined with SAR study
and biochemical screening

Specifically inhibits migration of
cells that express PRLs in a
dose-dependent manner and does
not affects proliferation of HEK
cells at 50 μM

114

Table 4 PRL inhibitors (Continued)
Inhibitor
Potency and Selectivity
Not phosphatase inhibitors,
Trimerization disruptors
Compound-43
30mg/kg cmpd-43 inhibits melanoma
and several
xenograft tumor growth; ~2μM cmpdanalogs.
43 suppress 50% MeWo cells survival
(estimated from Fig 5D)

Discovery
Sequential structure-based
virtual screening of
compounds of Asinex and
ChemBridge subsets in the
ZINC database.
Extracted from spice
turmeric, has been known to
be able to induce apoptosis
of cancer cells and suppress
cell migration and
angiogenesis.

Ginkgetin and
sciadopitysin

Inhibited PRL3 activity:
gfinkgetin: IC50 = 50 μM
sciadopitysin: IC50 = 25.8 μM
Not tested on other PTPs and PRLs

Bioflavonoids identified in
the MeOH extract of the
young branches of Taxus
cuspidate

Inhibited PRL3 activity:
Compound 1: IC50 = 5.2μg/ml
Compound 2: IC50 = 1.3 μg/ml
Not tested on other PRLs and PTPs.

Extracted from the roots of
Rubia akane.
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Curcumin

Inhibit human PRL3 activity PRL3:
IC50 = 31 μM
Shows acceptable selectivity against
PTP1B, TCPTP and VHR and no
selectivity against PRL1 and PRL2

Natural
anthraquinone
compounds:
compound 1
and 2

Cellular efficacy
Specifically inhibit cell
proliferation and migration of
PRL-1 overexpressing cells;
suppress MeWo cells
proliferation and migration,
inhibit melanoma xenograft
tumor growth.
Inhibits mRNA expression of
PRL3 and partial PRL2;
specifically inhibits adhesion
and migration of cancer cells
with high PRL3 expression;
inhibits growth and metastasis of
xenograft tumors in mice.

Ref.

115

116

Reduce invasiveness of B16F10
cells in vitro

117

Compound 2 was shown to
inhibit migration of DLD-1 cells
but not proliferation.
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Table 4 PRL inhibitors (Continued)
Inhibitor
Potency and Selectivity
PRL1 and
PRL3 mAb
(mouse);
Chimeric
mouse and
human PRL3
mAb;
PRL3- zumab

High selectivity: PRL1 and PRL3
mAb only prevents metastatic tumor
formation of cells that express
respective PRL.
PRL3-zumab is more potent than 5FU, a first-line chemotherapeutic drug
for gastric cancer.

Discovery

Generated using hybridoma
technology and their
specificity was confirmed.

Cellular efficacy
Efficiently and specifically
block metastatic tumors
formation of cells
overexpressing PRL; also inhibit
tumor formation of cancer cells
expressing endogenous PRL;
prevents recurrence of PRL3
positive tumors after surgery.

Ref.

50,105,
119
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CHAPTER 3. PRL-3 DRIVES MIGRATION AND PROGRESSION OF T-ALL
IN VITRO AND IN VIVO
3.1

Hypothesis and Specific Aims

As discussed in Chapter 2, the oncogenic role of PRLs is well established, and they
are considered attractive therapeutic targets in cancer. Before we move from bench to
bedside, there are still critical questions need to be answered. For example, what are the
physiological substrates of PRLs? What are the substrates in malignant conditions? Are the
substrates dependent on cancer type? How are PRLs involved in regulating tumor
progression? How can we develop specific PRL-3 inhibitors to facilitate more in-depth
study of PRL-3 or for therapeutic purposes?
While the role of PRL-3 is well documented in solid tumors, its role in leukemia is
less well defined and how PRL-3 contribute in T-ALL has not been reported. Our
preliminary research suggests that PRL-3 could play an important role in T-ALL. Our lab
previously performed an unbiased serial transplantation screen in the zebrafish Mycinduced T-ALL model to identify genes and pathways that were highly expressed in TALL clones as they evolved relapse potential, defined as acquisition of aggressive growth,
increased self-renewal, and resistance to chemotherapy. RNAseq comparing these clones
pre- and post-evolution showed that a subset of those with high relapse potential acquired
high expression of PRL-3. Realtime RT-PCR analysis showed that PRL-3 was highly
expressed in the zebrafish T-ALL samples that evolved high relapse potential but not in
the samples with low relapse potential or in the normal whole blood/T cells, suggesting
that PRL-3 could play a role in cell growth, maintenance of stemness or drug resistance.
Given the oncogenic role of PRL-3 in multiple cancers, I hypothesized that PRL-3 plays a
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critical role in T-ALL progression by affecting cell survival, proliferation and/or
migration. To test this hypothesis, three specific aims are developed: 1) To determine
whether PRL-3 shows clinical relevance in T-ALL progression and relapse; 2) To
determine whether PRL-3 affects T-ALL cells survival, proliferation or migration. 3) To
identify PRL-3 substrates or interactomes.
3.2
3.2.1

Materials and Methods
Materials

PE Anti-Human CD45 was obtained from Giolegend (Clone HI30, 304008). Mouse
IgG-HRP and rabbit IgG-HRP were from Cell signaling (7106, Lot TC2625) and GeneTex
(26741, Lot 9788061), respectively. Since the PRL antibody is notorious for its specificity
and high homologous between PRLs leads to non-specific recognition, different PRL-3
antibodies were obtained to test their specificity. Same amount of PRL-1, PRL-2 or PRL3 (0.3 ug) was loaded and different PRL antibody was used for western blot analysis. PRL3 antibody (Abcam50276) was shown to recognize PRL-3 but not PRL-1/2 while PRL pan
antibody (R&D MAB32191) showed similar sensitivity to PRL-1 and PRL-2, but barely
detects PRL-3 (Figure 3A). Therefore, all the Western blots about PRLs shown in the
thesis are obtained using these two Abs.
The PRL inhibitor, JMS-053, was kindly provided by Dr. John S. Lazo, Elizabeth
Sharlowe, and Peter Wipf (University of Virginia, Charlottesville, VA, USA), and the Src
inhibitor, SU6656, was purchased from Sigma-Aldrich (S9692, St. Louis, MO, USA).
Lentiviral packaging plasmids psPAX2 (Addgene 12260, Watertown, MA, USA)
and pMD2.G (Addgene 12259) were gifted from Didier Trono. pLenti PGK Puro DEST
(w529-2) (hereafter referred to as PGK) (Addgene 19068) and pLenti PGK GFP Puro
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(w509-5) (Addgene 19070) were gifts from Eric Campeau & Paul Kaufman. Non-targeting
control pLKO shRNA lentivirus plasmid (MISSION, SHC002, Sigma-Aldrich) was kindly
provided by Tianyan Gao and pLKO shRNAs targeting PRL-3 were purchased from
Sigma-Aldrich; target sequences are listed in Table 5.
pENTR:PRL-3 (human) and pENTR:prl-3 (zebrafish) Gateway Entry constructs
were made by PCR amplifying PRL-3 and prl-3 from cDNA generated from human TALL cells and 24h post-fertilization zebrafish embryos, respectively. The PCR products
were subcloned into the pENTR-d-TOPO cloning vector (ThermoFisher K2400-20,
Waltham, MA, USA). The Gateway compatible zebrafish rag2 vector and generation of
the rag2:Myc and rag2:mCherry construct has been previously described120. The
PGK:PRL-3 and rag2:prl-3 constructs were generated using the PGK destination vector
and pENTR:PRL-3 or the rag2 destination vector and pENTR:prl-3 along with Gateway
LR Clonase II enzyme mix, according to manufacturer’s protocol (ThermoFisher
11791020).
Frozen isolated PBMCs from de-identified T-ALL patients were kindly provided
by Dr. Michelle Kelliher (University of Massachusetts Medical School, Worcester, MA,
USA). PBMCs from healthy donors were purchased from Precision for Medicine
(Bethesda, MD, USA).
3.2.2 T-ALL Cell Lines and Cell Culture
All the human T-ALL cell lines used in the study were authenticated by short
tandem repeat (STR) DNA profiling and tested for mycoplasma contamination prior to
experimentation. Cells were grown in RPMI1640 (ThermoFisher 11875119)
supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals,
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S11150H, Lot M17161, Flowery Branch, GA, USA). Cells were cultured at 37°C in a
humidified atmosphere with 5% CO2.
3.2.3

Western Blot

Western blot analysis was performed using a stain-free technology developed by
BioRad, which allows us to use the total protein as the loading control121. For all figures
shown, a band of total protein ~50kD size is used to represent the lane of total protein.
An example was shown in Figure 3B.
3.2.4

Microarray Data Analysis

The primary patient microarray datasets were accessed through the Gene
Expression Ominbus (GEO) at NCBI (https://www.ncbi.nlm.nih.gov/geo), including
GSE13159122,123, and 124,125
3.2.5

Lentivirus Packaging and T-ALL Cells Infection

For PRL-3 knock-down, lentivirus was produced in 293T cells using TransITLT1 (Mirus Bio, Madison, WI, USA), according to the manufacturer’s instructions using
scrambled or shPRL-3 plasmids. For T-ALL cell infection, 2.5mL virus with 10μg/mL
polybrene (Thermo Fisher Scientific TR-1003-G) was added to 5x105 cells and
centrifuged at 2250 rpm for 90 minutes. Virus was washed out with PBS after 24h, and
cells were selected in culture media with 5μg/mL puromycin for 48h before experiments.
To generate PRL-3-ovexpressing cell lines, 293T cells were transfected with
PGK:GFP with or without PGK:PRL-3 as described above. T-ALL cells were infected
with spin cycles and selected in medium with 5μg/mL puromycin (Jurkat) or 2μg/mL
puromycin (HBPALL) for one week to produce stably expressing cell lines, then
maintained in media with puromycin thereafter.
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3.2.6

In Vitro Cell-based Assays

The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570, Madison,
WI, USA) was used to measure cell survival according to the manufacturer's instructions.
A Synergy LX BioTek (Winooski, VT, USA) multi-mode plate reader was used to read
luminescent signal.
Migration assays were performed as previously described69. Cells were starved in
serum free medium overnight at the same density, then the cells were spun down and
resuspended in serum free medium and plated in upper chamber of the transwell support.
After 4 hours, the cells that migrated into the lower chamber were quantified by
CellTiter-Glo Luminescent Cell Viability Assay.
Cell cycle was analyzed by quantifying 5’-ethynyl-2’-deoxyuridine (EdU) uptake
using ClickIT EdU Alexa Fluor 647 (Thermo Fisher Scientific, C10424) according to the
manufacturer’s protocol. DAPI (0.1μg/ml) (ThermoFisher 62248) was also used to stain
the DNA.
Apoptosis was quantified by staining cells with Annexin V APC (ThermoFisher
88-8007-74) according to the manufacturers protocol in the presence of DAPI
(0.05μg/ml).
3.2.7

Zebrafish T-ALL Models

Use of zebrafish was approved by the University of Kentucky’s Institutional
Animal Care and Use Committee (IACUC), protocol 2015-2225. Microinjections of
15ng/μL rag2:Myc + 45ng/μL rag2:mCherry or 15ng/μL rag2:Myc + 15ng/μL rag2:prl-3
+ 30ng/μL rag2:mCherry were used to generate zebrafish T-ALL in CG1 strain zebrafish
as previously described, and number of animals used in each group were chosen based on
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previous experiments90. Zebrafish were monitored for leukemia onset and progression
starting at 21 days post-fertilization (dpf) and every 3 days onwards by analyzing percent
of the body expressing mCherry-positive leukemia cells using a Nikon fluorescenceequipped SMZ25 microscope. Circulating mCherry-positive T-ALL was noted by
examining the vessels within the tail vasculature. Animals were monitored until 90 dpf or
until they had to be sacrificed due to leukemia burden. Animals that died before the end
of the monitoring period without leukemia progression outside the thymus were
excluded. Zebrafish leukemias were harvested and cytospin and May-Grunwald Giemsa
staining were performed as previously described before imaging on a BioTek Lionheart
FX microscope120,126. To assess gene expression, RNA was isolated from the cells using
Zymo Research Quick-RNA kit (R1054, Irvine, CA, USA). Total RNA was reverse
transcribed (BioRad iSCRIPT, 1708891) and real time PCR performed using iTaq
Universal Sybr Green Supermix (Biorad, 1725120) with primer sequences available in
Table 5. Data were normalized to ef1a expression and fold change was calculated using
the 2-∆∆Cq method.
3.2.8

Xenograft Models in Immune-compromised Mice

Use of mice was approved by the University of Kentucky’s IACUC, protocol
2017-2754. Eight-week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were
obtained from Jackson Laboratory (Bar Harbor, ME, USA). Eight mice per group were
used for experiments based on pilot studies that utilized three mice per group. The mice
were randomized by placing into groups such that the difference between average group
weight is not greater than 10%. Jurkat cells were infected with Scrambled shRNA or
PRL-3 shRNA as described above. Two days after virus infection, Jurkat cells were
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selected using 5μg/ml puromycin for two days, stained with trypan blue, and viable cells
were FACS isolated. 106 live cells in 100μL PBS were injected intravenously. Peripheral
blood samples (100-150μL) were collected by submandibular bleeding at 4, 6, and 8
weeks post-transplantation and stained with human CD45 antibody according to
manufacturer’s protocol and analyzed by flow cytometry.
3.2.9 Statistical Analysis
Results are shown as mean ± standard deviation. Microarray expression analysis
was supported by Biostatistics and Bioinformatics Shared Resource Facility at University
of Kentucky. Sample sizes of mice study were chosen based on pilot experiments
utilizing 3 samples per group, and experiments were done unblinded. At least 3 biological
replicates were performed in each experiment. Statistical analyses were performed using
GraphPad Prism 7 (San Diego, CA, USA), combining data from all samples across all
replicates. Two-tailed t-tests were performed to compare two groups with similar
distribution, and Analysis of Variance (ANOVA) with Tukey’s multiple comparisons
was used to compare more than two groups. Human microarray data were analyzed using
two-sample t-test and Wilcoxon rank sum tests, and survival curves were analyzed using
Log-rank tests. Difference in circulating zebrafish cells was analyzed using two sample ttest between percents. All bar graphs shown are data pooled from ≥3 experiments.
3.3
3.3.1

Results
PRL-3 is Highly Expressed in T-ALL

Given the important role of PRL-3 in solid tumor progression and the fact that it
is under-explored in leukemia, it is important to identify the function of PRL-3 in T-ALL.
First PRL-3 expression was examined in bone marrow samples from T-ALL patient and
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healthy donors using gene expression datasets deposited in the Oncomine database
(GSE13159). These data revealed that PRL-3 mRNA expression is significantly higher
(p=6.8e-10) in T-ALL samples (n=174) compared to that from healthy donors (n=72,
Figure 4A). In GSE14615, we saw no significant difference in PRL-3 expression between
patients who achieved complete remission (n=29) versus those that relapsed (n=11) or
suffered induction failure (n=7, Figure 4B). However, the sample size was relatively
small in this study, and further investigation is warranted to determine whether PRL-3
expression is a predictor for T-ALL treatment failure. Western blot showed 3 out of 8 TALL patient peripheral blood mononuclear cell (PBMC) samples, which contain high
percentage of circulating leukemic cells, expressed very high PRL-3, while it is detected
at low levels, if at all, in PBMCs from 5 healthy donors (Figure 4C).
Additionally, PRL-3 protein was expressed at varying levels across 14 T-ALL cell
lines (Figure 5A). Interestingly, PRL-3 expression in the same cell line fluctuated
notably across independent assays (Figure 5B), although we did not find the expression
level to be related to cell density or serum deprivation.
Analysis of other PRL family members showed that PRL-1 expression was
significantly lower in primary T-ALL patient samples compared to healthy bone marrow,
while PRL-2 expression is significantly higher (Figure 6A and 6B). Consistent with
gene expression datasets, PRL-1 was not detected across T-ALL cell lines, while PRL-2
is expressed in most T-ALL cell lines examined (Figure 7A and 7B).
3.3.2

PRL-3 Promotes Cell migration, but Not Growth, in T-ALL Cells

PRL-3 knock-down or inhibition has been shown to impair cell growth in solid
tumor cell lines57,112. In order to define the role of PRL-3 in T-ALL, shRNAs were used
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to knock down PRL-3 expression in Jurkat cells, a T-ALL line with high endogenous
PRL-3 expression. Western blot analysis of samples collected four days after lentiviral
infection of shRNA constructs showed that PRL-3 was successfully knocked-down by
shRNA constructs #2 and #3 compared to scrambled (SCR) control shRNA (Figure 8A).
Expression of PRL-2 did not increase to compensate for PRL-3 loss and again, PRL-1
was not detected (Figure 8A). Interestingly, despite puromycin selection of the shRNA
construct, PRL-3 expression levels recovered over time (Figure 8B), suggesting that cells
with higher PRL-3 expression may outcompete those with stronger knock-down.
Cell growth of PRL-3 knockdown Jurkat cells was compared to controls cell,
which were transfected by scrambled shRNA (SCR). Cells subjected to 5μg/ml
puromycin selection for 2 days were plated and cell growth were measured by CellTiter
Glow assay up to 3 days. Unexpectedly, PRL-3 knockdown did not negatively impact
cell growth (Figure 9A).
As previous studies have shown that PRL-3 is also involved in solid tumor cell
migration127,128, we next examined whether PRL-3 knockdown affects cell migration
since migration of leukemic cells might be related to their capacity of central nervous
system (CNS) infiltration129. PRL-3 knock-down Jurkat cells were serum starved, then
their ability to migrate through a trans-well towards a serum stimulus over a 4h period
was quantified. As shown in Figure 9B, silencing PRL-3 expression significantly
reduced cell migration by ~50% (p<0.02). Similarly, when we overexpressed PRL-3 in
Jurkat and HBP-ALL cells (Figure 10A), we found no significant difference in cell
growth (Figure 10C), but significantly increased migratory capability compared to
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control (p≤0.009, Figure 10B). Together, these data suggest that PRL-3 plays an
important role in regulating cell migration, but not cell growth, in T-ALL cells in vitro
3.3.3

PRL-3 Knock-down Impairs Human T-ALL Engraftment in a Xenograft
Mouse Model

In order to determine whether silencing PRL-3 expression in human T-ALL
affects its oncogenic ability in vivo, xenotransplantation of T-ALL was performed using
PRL-3 knock-down Jurkat cells. As shown in Figure 11A, Jurkat cells expressing a
scrambled shRNA or a shRNA targeting PRL-3 were injected intravenously into
immune-compromised mice. At 4, 6, and 8 weeks after transplantation, blood samples
were collected and stained with anti-human CD45. Flow cytometry showed no human
CD45-positive cells in the circulation of mice injected with PRL-3 knock-down Jurkat
cells, while mice injected with Jurkat expressing scrambled shRNA cells showed
increasing numbers of CD45 positive cells in the blood each week (Figure 11B and
11C). Three mice harboring scrambled shRNA expressing T-ALL had to be euthanized
before the 8-week time point due to mobility issues likely resulting from T-ALL
infiltration into the spinal column, while mice with PRL-3 knock-down remained healthy
throughout the study. Together, these data show that PRL-3 significantly affects
engraftment and circulation of human T-ALL cells xenografted into mice.
3.3.4

PRL-3 Enhances T-ALL Onset in a Zebrafish Model

The elevated expression of PRL-3 in T-ALL patient samples and its role in
promoting migration in T-ALL cell lines suggests it may play an oncogenic role in TALL. A zebrafish Myc-induced T-ALL model, which was generated to express mouse cmyc under control of the zebrafish Rag2 promoter, was used to assess the role of PRL-3
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in T-ALL onset and progression. It has been shown that T-ALL arose in the zebrafish
thymus, then spread locally into gill arches and retro-orbital soft tissue, and eventually
spread to skeletal muscle and abdominal organs120,126
In our study, one-cell stage zebrafish embryos were injected with plasmids
containing rag2:Myc with rag2:mCherry, and with or without rag2:prl-3. Zebrafish prl-3
has 88% homology to human PRL-3 with conservation of the critical domains130.
Leukemia developed in the fish that incorporated mouse Myc in their chromosome. As
the leukemia cells also express fluorescent protein mCherry, T-ALL onset and
progression in these fish were monitored by using fluorescent microscope. Growth of TALL growth was quantified by the percent mCherry-positive cells within the body of the
animal; >70% mCherry-positive was considered leukemic. It was observed that T-ALL
develops in zebrafish from the thymus and expands into local tissues before entering the
circulation. Zebrafish T-ALL that expressed prl-3 consistently expanded from the thymus
earlier than T-ALLs expressing Myc alone (Figure 12A), and there was significant
difference in time to full leukemia onset between the groups (Figure 12B).
Because the T-ALL cells were fluorescently labeled, the time at which leukemia
cells begin to circulate was determined by visualizing cells within the vasculature in the
tail fin (Figure 13A, Supplemental Videos 1 and 2131). While more than half of animals
with T-ALL in the Myc-expressing group never developed circulating disease by >100 d (
Supplemental Video 1131), more than 80% of the Myc+prl-3 expressing T-ALLs were
circulating at a median time point of 42d, p=0.05 (Figure 13B, Supplemental Video 2
92

).
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The lymphoblasts were morphologically similar between the groups (Figure
14A), and there was no significant difference in Myc expression between Myc and
Myc+prl-3 T-ALL samples (Figure 14B). Gene expression analyses indicated that both
the rag2:Myc and rag2:Myc+rag2:prl-3 leukemias expressed the lymphocyte specific
genes rag1 and rag2 and the T-cell genes lck and tcrB-C2, but not B-cell related genes
Pax5, igD or igM, indicating all leukemias generated were of T-cell origin. We verified
that the rag2: Myc+rag2: prl-3 leukemias expressed >10-fold higher levels of Prl-3 than
the Myc control group (Figure 14C). Interestingly, endogenous prl-3 expression was also
significantly higher in the rag2: myc T-ALLs than normal blood, suggesting that PRL-3
may be an important collaborating oncogene in T-ALL development.
Taken together, these data suggest that PRL-3 can play an important role in TALL onset and progression in vivo, likely by enhancing migration into local tissues and
contributing to the ability of the cells to enter circulation.
3.4

Discussion

Treatment outcomes of ALL have been improved dramatically over the last
several decades with survival rates exceeding 80%. However, there is a disparity in the
number of available immunotherapies and molecular targeted therapies available in TALL compared to other leukemia subtypes, correlating with a worse patient prognosis in
patients who fail traditional chemotherapy regimens. Additionally, CNS infiltration by TALL, both CNS and bone marrow relapse remain critical clinical challenges, with
survival rates of relapsed disease as low as 40%132. The identification and
characterization of important drivers of T-ALL progression is needed for the design of
novel, targeted therapeutics.
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We found PRL-3 was highly expressed in T-ALL patient samples and cell lines,
consistent with studies reporting PRL-3 up-regulation in solid tumors133 and B-ALL64.
Importantly, we used two different animal models to demonstrate an oncogenic role of
PRL-3 in T-ALL, which, to our knowledge, is the first in vivo study demonstrating an
oncogenic role for PRL-3 in T-ALL. The overexpression of PRL-3 in the transgenic
zebrafish T-ALL model showed that PRL-3 expression enhanced the spread of T-ALL
cells out of the thymus and promoted their rapid entry into circulation, while human TALL cells with silenced PRL-3 lost their ability to engraft and grow in NSG mice. While
we hypothesize the lack of T-ALL engraftment associated with PRL-3 knock-down may
be attributed to a decreased ability of the leukemia cells to migrate and home to the bone
marrow or thymus niche after xenograft, this needs to be confirmed experimentally.
Given PRL-3 is established as enhancing viability and preventing apoptosis in other
cancers70, PRL-3 might be playing additionally roles in vivo that contribute to fitness of
the T-ALL cells.
Overall, our study suggests that PRL-3 functions in T-ALL to promote cell
migration, both in vitro and in vivo. While cell migration is critical to solid tumor
progression, and PRL-3 has well-established roles there, in leukemia, the contribution of
migration towards disease progression is less defined. In T-ALL, CCR7, a known
regulator of T lymphocyte migration, has been demonstrated to be necessary and
sufficient to drive infiltration of T-ALL cells into the CNS in a mouse model129. Another
regulator of cell migration, CXCR3, has also been reported to be involved in ALL
progression, in which CXCR3 inhibition significantly reduced leukemic infiltration into
bone marrow, spleen and CNS134. Although whether PRL-3 can modulate known
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lymphocyte migratory signals, such as CCR7 or CXCR3, to promote T-ALL migration
and possibly CNS relapse remains to be determined; there is clearly a precedent for
migration playing a critical role in ALL progression.
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Figure 3. Antibody Specificity and Total Protein as Loading Control for Western
Blot.
(A) Antibody against PRL-3 (Abcam, 50276) detects purified PRL-3 protein specifically
but not PRL-1 and 2. Human PRL pan specific antibody (MAB3219) detects both PRL-1
and PRL-2 at similar sensitivity but barely detects PRL-3. Recombinant human PRL-1
(8490-PT), PRL-2 (6694-PT) and PRL-3 (8455-PT) proteins were from R&D systems
and 0.3 μg of each protein was loaded in 4-20% protein TGX stain-free gel (BioRad, cat
#4568093).(B) All the Western blot analysis were performed using a stain-free
technology developed by BioRad, which uses total protein loaded for each sample as the
loading control. Protein was separated on TGX-stain free pre-casted 4-20% SDS gel,
which allows the image of total protein, as shown in left, by exposing the gel under the
UV activation in the ChemiDoc Imaging System. Representative bands from the total
protein gel instead of the whole image of the gel were shown in the Western blots results
in order to save space.
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Figure 4. PRL-3 is Highly Expressed in Human T-ALL Patient Samples.
(A) Microarray expression analysis of GSE13159 comparing PRL-3 expression in bone
marrow samples from T-ALL patients to that from healthy donors **p=6.8e-10. (B)
Analysis of GSE14615 comparing PRL-3 expression between samples from T-ALL
patients achieving remission and the patients with induction failure. NS=not significant.
(C) Representative western blot analysis of primary patient T-ALL samples compared to
PBMCs from healthy donors. Representative bands from total protein loaded were used
for loading control.
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Figure 5. PRL-3 is Highly Expressed in T-ALL Cell Lines
(A) Representative western blot analysis of human T-ALL cell lines, showing PRL-3
expression. Representative bands from total protein loaded were used for loading control.
(B) Quantification of 3 independent western blots across cell lines, showing PRL-3
expression can vary, even within the same cell line. *p<0.05, compared to PBMCs.
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Figure 6. High expression of PRL-2 in Human T-ALL Patient Samples
(A) Microarray analysis of GSE14615 showing PRL-1 is down-regulated in bone
marrow samples from T-ALL patient compared to that from healthy donors. *p<0.001.
(B) Microarray analysis of GSE14615 showing PRL-2 is up-regulated in bone marrow
samples from T-ALL patient compared to that from healthy donors **p<0.0001.
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Figure 7. PRL-2 Protein is Highly Expressed in T-ALL Cell Lines
(A) Representative western blot analysis of PRL-1 and PRL-2 in human T-ALL cell
lines, showing PRL-2 expression in a subset of T-ALL cell lines. Representative bands
from total protein loaded were used for loading control. (B) Quantification of 3
independent western blots cross human T-ALL cell lines, showing that PRL-2 expression
can vary, even with the same cell line.
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Figure 8. PRL-3 Knock-down in T-ALL Cells
(A) Representative western analysis figure showing PRL-3 expression was inhibited in
Jurkat T-ALL cells 4d post-infection with lentivirus carrying shRNA. PRL-2 expression
does not change upon PRL-3 knockdown, indicating PRL-2 does not compensate for
PRL-3 loss. Numbers represent relative expression of PRL-3 or PRL-2 protein,
normalized to total protein and compared to scrambled (SCR) control. (B) Jurkat cells,
which showed PRL-3 complete knock-down at day 5 post lentiviral infection (Figure
8A) were cultured for 6 and 7 days and total protein was extracted for western blot
analysis, showing that PRL-3 expression returns over time. The numbers in the blot are
relative expression normalized to total protein loaded.
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Figure 9. PRL-3 Knockdown Inhibits Cell Migration.
(A) Cells infected with SCR or PRL-3 knock-down shRNA were cultured in media 4
days post-infection with 5μg/ml puromycin for 72 additional hours. Cell growth was
determined by Cell Titer-Glo assay and normalized to the readout of day 0 and showed
no difference between groups. Data shown are the average of 3 independent experiments,
done in triplicate, NS=not significant. (B) Knock-down of PRL-3 in Jurkat cell line
reduced migration towards a serum stimulus more than 50%. Migration was normalized
to the cells infected by SCR shRNA, p<0.05 compared to SCR control.
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Figure 10. PRL-3 Over-expression Promotes Cell Migration in T-ALL
(A) Western blot analysis showed expression of PRL-3 in Jurkat and HBP-ALL cell
lines after infection with lentivirus harboring PGK: GFP or PGK:PRL-3. (B) High PRL-3
expression increased cell migration in T-ALL cells. Migration was normalized to control
cells expressing GFP only, **p<0.001, ***p<0.0001. For all bar graphs, data are the
average of at least three independent experiments, done in triplicate. (C) T-ALL cells
expressing PGK: PRL-3 (PRL-3 OE) or PGK:GFP (GFP) were cultured in medium with
puromycin for 72 hours. Cell growth was determined by Cell Titer-glow assay and
normalized to the readout of day 0, and showed no difference between PRL-3
overexpressing cells and control cells at all time points. Data shown are the average of 3
independent experiments, done in triplicate, NS= not significant.
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Figure 11 PRL-3 Knock-down Impairs T-ALL Engraftment in Mice.
(A) Schematic diagram of the xenotransplantation assay. (B) Representative flow
cytometry analysis of submandibular blood sample after human CD45 staining. (C)
Quantification of human CD45 staining of mice blood at week 4,6 and 8 after
transplantation. Each dot represents one mouse, the horizontal line represents the mean
value, and the standard deviation is shown, *p<0.01 and **p<0.001 compared to shRNA
control xenografted mice.
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Figure 12. PRL-3 Enhances Leukemia Onset in a Zebrafish T-ALL Model.
(A) Representative images of transient transgenic zebrafish expressing rag2:
Myc+rag2:mCherry (n=11) or rag2:Myc+rag2:mCherry+rag2:prl-3 (n=6) at 34 days
post-fertilization (dpf). (B) Kaplan-Meier analysis of time (days) percent survival (>70%
of animal is mCherry-positive). Data shown in this figure were collected and analyzed by
Meghan Haney.
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Figure 13. PRL-3 Enhances Leukemia Circulation in a Zebrafish T-ALL Model.
(A) Representative rag2: Myc+rag2:mCherry+rag2:prl-3 animal, showing circulating
mCherry+ leukemia cells within the tail fin. (B) Kaplan-Meier analysis of time (days) for
each T-ALL to be visualized in circulation, * p=0.049. Data shown in this figure were
collected and analyzed by Meghan Haney.
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Figure 14. Prl-3 is Highly Expressed in Leukemia Zebrafish T-ALL Model.
(A) Representative images of May-Gunwald Giemsa staining of blood samples from fish
from each leukemia type. Scale bar=100μm. (B) Realtime RT-PCR analysis of Myc
expression between rag2 :Myc+rag2:mCherry (n=8) and rag2: Myc + rag2: mCherry +
rag2: prl-3 (n=5), showing that Myc expression is not differentially expressed between
the groups. Each point represents one fish sample. NS=not significant. (C) Realtime RTPCR analysis of lymphocyte, T-cell, and B-cell specific genes, demonstrating that
leukemia is of T-cell origin. Bars are the average expression of three samples per group.
Data shown in this figure were collected and analyzed by Meghan Haney.
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Table 5 shRNA Sequence Used for PRL-3 Knock-down
ShRNA
PRL-3 shRNA#1

Target sequence
CTACAAACACATGCGCTTCCT

PRL-3 shRNA#2

TCTCGGCACCTTAAATTATTA

PRL-3 shRNA#3

ACCGTTGTGGACTGGCCGTTT

Table 6 Realtime RT-PCR Primer Sequences
Gene

Forward Primer

Reverse Primer

Purpose

z-ptp4a3

GGTGTCACGACAGTGGTCAG

TCAATCAAGGCCACAGCCAC

PRL-3
expression

z-rag1

AGCAATGATGCAAGGCAGAG

TGTGCAGGGGCTGGAATATC Lymphocytes

z-rag2

AGCTCTCAGATTTCGGAGTACAC

ACAAGGCTGCCACAATTCAC Lymphocytes

z-lck

AGAAGATCTCGATGGTTTGTCTGT

CGCAGTTCCCCATGTTTACG

T-cell

z-tcr β-c2

ATTCACCTGCACTGTCCGAT

AGCTTCAATCCCTTCGGCTT

T-cell

z-pax5

CTGATTACAAACGCCAAAAC

CTAAATTATGCGCAGAAACG

B-cell

z-igD

GAGAGCAGCAAAAGGATGGC

TGCAAGTTTGGTCTTGTTCTGC

B-cell

z-IgM-VH1

CATGACAATGGATATTGTGTCC

ACATGAAGGTTGCTGATCCAC

B-cell

m-Myc

AGCGACTCTGAAGAAGAGCAA

GCACCTCTTGAGGACCAGTG

/

eef1a1

ATGGCACGGTGACAACATGCT

CCACATTACCACGACGGATG normalizing
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CHAPTER 4. PRL-3 REGULATES SRC PATHWAY TO PROMOTE CELL
MIGRATION
4.1

Introduction

In vitro and in vivo data suggest that PRL-3 functions in T-ALL progression
likely by modulating leukemia cell migration. Since PRL-3 is a phosphatase and multiple
oncogenic signaling pathways are shown to be regulated in cancer cell models as
discussed in Chapter 2, it is possible that PRL-3 affects critical signaling pathways
involved in cell migration via de-phosphorylation. To test this hypothesis, we next
examined the gene signatures related to PRL-3 high expression in T-ALL patients and
signaling pathways that are affected by PRL-3 knockdown or ectopic expression in TALL cells at protein level.
4.2
4.2.1

Materials and Methods
Materials

Antibodies used in this study, including their manufacturer, catalog number, lot
number, blocking buffer used, and dilution factor are listed in Table 7.
4.2.2

Co-immunoprecipitation

Cells (~50 million) were lysed in Pierce IP lysis buffer (Thermo 87788)
supplemented with 1% Protease Inhibitor Cocktail (Sigma P8465). Total protein was
incubated with 80 μL Anti-Flag M2 magnetic beads (Sigma m8823) on shaker overnight.
After removing supernatant and washing the beads with PBS gently, the magnetic
beads were boiled with 50 μL SDS containing buffer to elute the immunoprecipitants
from the beads. Total cell lysates and immunoprecipitants were used for western blot
analysis.
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4.2.3

Gene Set Enrichment Analysis

Gene Set Enrichment Analysis was done using GSEA 4.0.0. PRL-3 expression
levels, corresponding to Affymetrix probes 209695_at and 206574_at were used for
phenotypic labeling. Enrichment was calculated using MSigDB collection C6, oncogenic
gene sets. Gene set enrichment was considered significant if it had a nominal p-value
<0.05.
4.2.4

RPPA Assay and Data Processing

Reverse Phase Protein Array (RPPA) and data analysis were performed by the
RPPA Core Facility at MD Anderson Cancer Center (Houston, TX, USA) as previously
described135. Briefly, total protein extracted from cells was printed on nitrocellulosecoated slides using an Aushon Biosystems 2470 Arrayer. Slides were probed with
antibodies previously validated by the core, and signals reflecting protein abundance
were visualized by a secondary streptavidin conjugated HRP and DAB colorimetric
reaction. The slides were scanned, analyzed, and quantified using Array-Pro Analyzer
software (MediaCybernetics) to generate spot intensity. SuperCurve GUI was used to
estimate relative protein levels (in log2 scale). A fitted curve ("supercurve") was created
with signal intensities on the Y-axis and relative log2 amounts of each protein on the Xaxis using a non-parametric, monotone increasing B-spline model. Raw spot intensity
data were adjusted to correct spatial bias before model fitting using “control spots”
arrayed across the slide. A QC metric was generated for each slide to determine slide
quality and only slides with 0.8 on a 0-1 scale were used. Protein measurements were
corrected for loading using median centering across antibodies. Samples with low protein
levels were excluded from further analysis.
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4.2.5

In Vitro Cell-based Assays

The CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7570, Madison,
WI, USA) was used to measure cell survival according to the manufacturer's instructions.
A Synergy LX BioTek (Winooski, VT, USA) multi-mode plate reader was used to read
luminescent signal.
Migration assays was performed as previously described49. In experiments using
JMS-053 or SU6656, cells were pre-treated with JMS-053, SU6656 or DMSO control for
2h before plating into the upper chamber. The cells that migrated into the lower chamber
were quantified by CellTiter-Glo Luminescent Cell Viability Assay.
4.2.6

Statistical Analysis

Results are shown as mean ± standard deviation. At least 3 biological replicates
were performed in each experiment. Statistical analyses were performed using GraphPad
Prism 7 (San Diego, CA, USA), combining data from all samples across all replicates.
Two-tailed t-tests were performed to compare two groups with similar distribution, and
Analysis of Variance (ANOVA) with Tukey’s multiple comparisons was used to
compare more than two groups. Human microarray data were analyzed using two-sample
t-test and Wilcoxon rank sum tests, and survival curves were analyzed using Log-rank
tests. All bar graphs shown are data pooled from ≥3 experiments.
4.3
4.3.1

Results
PRL-3 Regulates Src Activity in T-ALL Cells

To identify a mechanism by which PRL-3 might contribute to cell motility, we
first examined gene signatures associated with PRL-3 expression in T-ALL patient
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samples. T-ALL samples with high levels of PRL-3 (upper quartile) and low levels of
PRL-3 (lower quartile) were selected from GSE13159 (Figure 4A) for Gene Set
Enrichment Analysis (GSEA), which identified that genes linked with SRC kinase
signaling (Figure 15A ), embryonic stem cell signature (Figure 15B ), and VEGF
(Figure 15C ) pathways were significantly enriched in PRL-3 high T-ALL.
In order to examine the protein phosphorylation mediated by PRL-3, a high
throughput antibody-based functional proteomic analysis, Reverse-Phase Protein Array
(RPPA), was used to examine the differential protein expression in PRL-3 knockdown or
overexpressing cells. In this experiment, total proteins were extracted from Jurkat GFP
versus Jurkat PRL-3 OE cells or Jurkat cells transfected with scramble versus PRL-3
shRNA, denature by SDS, printed on nitrocellulose-coated slides, which are then probed
by 442 different proteins, including 86 phospho-proteins. The result showed 23 proteins
are greater than 20% differential expressed between Jurkat cells transfected with
scramble or PRL-3 shRNA (Figure 16A and Supplemental Table 270). RPPA on PRL-3
overexpressing Jurkat cells compared to control cells identified 21 proteins with more
than 30% differential expression (Figure 16B and Supplemental Table 370). Expression
of Histone-H3, Chk2, and Src_pY527 were affected in both PRL-3 knock-down and
overexpressing cells.
Both GSEA and RPPA data suggest that the SRC pathway is associated with
PRL-3 expression at both the mRNA and protein level. Src is a non-receptor kinase that
is activated in a large fraction of cancers, where it plays a prominent role in cell
migration and metastasis90. Src activity is regulated by phosphorylation, where Tyrosine
527 and tyrosine 416 are two critical phosphorylation sites that regulate Src activity

64

(Figure 17). Tyrosine phosphatases dephosphorylate the pTyr-527 to stabilize the
open/active conformation of Src. Further phosphorylation of tyrosine 416 locks the
catalytic pocket of Src into the fully active conformation. The fully activated Src then
phosphorylate its substrate proteins. The pTyr-527 of Src is also regulated by CSK (Cterminal Src Kinase), which add phosphorylation modification to Tyr 527, leading to
inhibition of Src activity. In other words, activation of Src pathway occurs by
dephosphorylation of the 527 residue and by phosphorylation of the 416 residue.
In order to validate the changes in Src pathway expression seen in RPPA studies,
Western blot was performed using PRL-3 knock-down or overexpressing T-ALL cell
lines. Cells with PRL-3 overexpression had decreased phosphorylation of Src_p527 at all
time points compared to control (Figure 18A-B), while total Src protein expression was
not affected. Conversely, PRL-3 knock-down in Jurkat cells increased total Src protein
expression and phosphorylation of Src_Y527 (Figure 19A-B). Interestingly, CSK
expression was inversely correlated with PRL-3 expression (Figure 18A and 19A),
consistent with previous reports that found PRL-3 down-regulates CSK expression in
human embryonic kidney cells and colon cancer cell91.
Together, these data show that genetic manipulation of PRL-3 in T-ALL cells can
modulate Src activity by affecting phosphorylation of Src itself as well as affecting
expression of kinases known to phosphorylate Src.
4.3.2

Src is not a PRL-3 Direct Substrate

The effect of PRL-3 on phosphorylation of Src_Y527 may be through a direct
action of PRL-3 phosphatase activity or through an indirect mechanism such as
regulation of CSK or other proteins. In order to answer this question, a PRL-3 mutant,
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PRL-3 (C104S) was used in the following study. The PRL-3 (C104S) mutant is
phosphatase deficient but still retain the binding affinity to its substrates. Over-expressing
PRL-3 (C104S) mutant in Jurkat cells partially rescued the reduction of Src_Y527
phosphorylation compared to PRL-3 wild-type expression (Figure 20A-B), suggesting
that PRL-3 phosphatase activity likely plays a role in Src regulation. Importantly, PRL-3
(C104S) has been previously shown to retain a low level of phosphatase activity48; the
artificially high level of exogenous PRL-3(C104S) expression in the Jurkat cells may
therefore compensate for reduced phosphatase activity, leading to incomplete rescue of
the phosphorylation of Src_Y527.
Next, Jurkat cells expressing 3XFlag PRL-3 or PRL-3 (C104S) was used for coimmunoprecipitation assay to determine whether PRL-3 is physically associated with Src.
Interestingly, Src did not co-immunoprecipitate with Flag-tagged PRL-3 or PRL-3
(C104S), despite being found at high levels in Jurkat cell lysate (Figure 20C). Our results
indicate that Src is not a direct substrate of PRL-3 in T-ALL and PRL-3 modulates
Src_Y527 phosphorylation by either inhibiting CSK expression, or via an unknown
protein intermediate (Figure 20A and 20D).
4.3.3

PRL Inhibitor, JMS-053, Inhibits T-ALL Cell Migration via Src Pathway.

T-ALL migration plays a critical role in T-ALL progression and our data show
PRL-3 can directly affect the migratory phenotype of T-ALL cells both in vitro and in
vivo. As small molecule inhibition of PRL-3 can block solid tumor progression70, it
would have translational potential if PRL-3 inhibition by small molecules also shows
similar effects. JMS-053, the most potent and specific PRL inhibitor, was used to
examine how PRL-3 inhibition affects T-ALL. This non-competitive PRL inhibitor, JMS-
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053102, significantly reduced the viability of T-ALL cells in a dose dependent manner
(Figure 21A), with lesser to no effects in cell lines that did not routinely express high
levels of PRL-3. PRL-3 inhibition increased apoptosis in T-ALL cells after 24h, although
this trend was not significant across multiple experiments (Figure 21B). PRL-3 inhibition
did not show any effect on cell cycle, measured by EdU uptake (Figure 21C). Short-term
(<2hr) JMS-053 treatment significantly (p<0.001) impaired the migration capability of all
PRL-3 expressing T-ALL cell lines tested, reducing cell migration through a transwell
towards a serum stimulus by 30-80% (Figure 22A). JMS-053 treatment increased the
phosphorylation Src_Y527 (Figure 22B), again indicating that PRL-3 might promote cell
migration by activation of Src.
Finally, in order to determine whether the effect of JMS on cells migration is via
Src pathways, a Src inhibitor, Su6656, was used to treat PRL-3 over-expressing cells in
combination with JMS-053 and evaluated whether the inhibitors synergized to affect cell
migration capability. While both JMS-053 and Su6656 significantly decreased cell
migration compared to control, no significant additive effect was detected when both
inhibitors were used (Figure 22C), supporting the hypothesis that PRL-3 modulates Src
signaling to promote cell migration. Taken together, our data showed that small
molecule inhibition of PRL-3 blocks T-ALL growth and migration in vitro, likely due to
Src inhibition, and suggest that PRL-3 might be a useful target to control T-ALL
progression.
4.4

Discussion

Here we explored a mechanism how PRL-3 enhance T-ALL migration and
progression. We have demonstrated that PRL-3 modulates the Src signaling pathway in
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T-ALL cell lines. Src activation has been reported in many types of human cancer, with a
prominent role in regulating motility, migration, and metastasis90,136,137. PRL-3 has been
previously reported to play a role in Src pathway activation in solid tumors and benign
human cell lines91,138. Our study expanded the role of PRL-3 in Src signaling pathway
modulation to include T-ALL, suggesting that PRL-3 might be a central regulator of the
Src signaling network across multiple cancer types. However, we could not conclude
whether PRL-3 acts directly on Src protein to dephosphorylate the Y527 residue, or
whether it modulates expression CSK protein, causing an indirect decrease in Src_Y537
phosphorylation. Additionally, our RPPA analyses determined that the expression of
other proteins were affected by PRL-3, including Histone-H3, Chk2, JNK, Hes1, Rictor,
Axl, and Hif1-alpha, all of which play known roles in tumor progression, and may
represent novel mechanisms by which PRL-3 promotes T-ALL.
In summary, the oncogenic role of PRL-3 was expanded to T-ALL using both in
vitro and in vivo assays in our study. PRL-3 was found to promote T-ALL
development/onset in zebrafish models and play a role in engraftment in mouse xenograft
models. Importantly, we also found that chemical inhibition of PRL-3 can inhibit cell
growth and migration, suggesting that PRL-3 is a feasible therapeutic target in T-ALL.
Cell-culture based assays revealed that PRL-3 modulates Src signaling in T-ALL to
enhance migratory capability, with no significant effect on cell growth. Given that several
genes involved in T cell migration promote CNS and bone marrow relapse, further
studies on the role of PRL-3 in CNS infiltration and relapse of T-ALL are necessary. Our
findings present a strong rationale for developing targeted therapies targeting PRL-3
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signaling. There is increasing interest in developing PRL-3 inhibitors for use in solid
tumors; our study indicates that they may be useful in T-ALL as well.

69

Figure 15. GSEA Analysis Reveals Pathways Enriched in PRL-3 High patient
samples.
Gene Set Enrichment Analysis of T-ALL patient samples (GSE13159) comparing bone
marrow with high PRL-3 expression (upper quartile) vs low PRL-3 expression (bottom
quartile) identified that (A) SRC pathway, (B) Embryonic stem cell gene signatures, and
(D) VEGF (vascular endothelia growth factor) pathway.
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Figure 16. Reverse Phase Protein Array Analysis (RPPA)
of (A) PRL-3 knock-down or (B) over-expression of PRL-3 3 in Jurkat cells showed
differential protein expression when compared to controls. Red bars show any protein
that was up or down regulated 20%, and protein names shown in red are common in both
groups, and include Chk2, Histone H3, and Src_pY527.
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Figure 17. Schematic of Src Pathway
Src is one member of Src family tyrosine kinases, which is composed of SH3 (Src
homology 3) and SH2 (Src homology 2) domain, the kinase domain, and the C-terminus
regulatory tail. The phosphorylation of tyrosine residue (Tyr-527 and Tyr-416) in the Cterminus tail are crucial for the regulation of Src activity. This figure is adapted from136.
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Figure 18. Src Pathway is Activated in PRL-3 Overexpressing Jurkat Cells.(A)
Western blot validation of Src pathway in PRL-3 overexpressing Jurkat cells. Cells were
serum starved overnight and added to serum containing complete media for the indicated
time points. Src_pY527 and CSK protein were consistently decreased in PRL-3 overexpressing Jurkat cells but not GFP expressing control cells. Numbers shown represent
relative protein expression. (B) Quantification of Src_pY527 western blots representing
at least n=3 independent experiments in PRL-3 OE Jurkat cells. Box plots show the mean
and standard deviation.
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Figure 19. Src Pathway is Inhibited in PRL-3 Knockdown Cells
(A) Representative western blot analysis of Src_pY527, total Src, and CSK in Jurkat cells
with PRL-3 knock-down, and (B) quantification of at least 3 independent experiments in
PRL-3 knock-down cells, showing the mean and standard deviation of each group.
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Figure 20. Src is Not a Direct Substrate of PRL-3
(A) Representative western blot validation of Src pathway in 3×Flag PRL-3 Wt and
3×Flag PRL-3 C104S mutant Jurkat cells, showing that PRL-3 C104S overexpression
partially rescue reduction of Src_Y527 phosphorylation (B) Quantification of n=4
independent experiments analyzing SRC_pY527, *p=0.003. (C) Co-immunoprecipitation
assay of Jurkat overexpressing PRL-3 substrate trapping mutants, 3×Flag PRL-3 C104S
or 3×Flag PRL-3 C104D, did not pulldown Src. (D) Schematic of PRL-3 and modulation
of Src pathway in T-ALL cells.
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Figure 21. PRL-3 Inhibition does not Affect T-ALL Cell Apoptosis and Proliferation
(A) JMS-053 inhibits cell viability, evaluated by quantifying ATP production via CellTiter Glo, *p≤0.001 or NS=not significant, compared to DMSO. There is no significant
difference in apoptosis (B) or cell cycle (C) in JMS-053 treated cells, compared to
DMSO control.
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Figure 22. PRL-3 Enhances Migration of Jurkat Cells via Src Pathway
(A) JMS-053 treatment (10μM) for 2 h suppressed cell migration of T-ALL cells,
**p<0.001 compared to DMSO. For all, bars are the average of three experiments, each
done in triplicate, ± standard deviation. (B) JMS-053 (10 µM) treatment increased Src
phosphorylation at tyrosine 527. Blots are representative of at least 3 independent
experiments. The numbers in the blot are relative expression normalized to total protein
loaded. (C) Cell migration capability of PRL-3 over-expressing cells was compared
between groups treated with DMSO, Src inhibitor Su6656 (2.5μM), JMS-053 (10μM) or
in combination and showed no additive effects between Su6656 and JMS-053, NS=not
significant, ***p<0.05.
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Table 7 List of Antibodies, Their source and Working Dilutions
Host Working
species dilution

Reagents

Source

Anti-Src

Cell Signaling (Clone 32G6, 2123, Lot 5)

Rabbit

1:1000

Anti-Src_pY416

Cell Signaling (Clone D49G4, 6943, Lot 4)

Rabbit

1:1000

Anti-Src_pY527

Cell Signaling (2105, Lot 9)

Rabbit

1:1000

Anti-CSK

Cell Signaling (Clone C74C1,4980, Lot 2)

Rabbit

1:1000

Mouse IgG-HRP

Cell Signaling (7106, Lot TC2625)

Goat

1:5000

Rabbit IgG-HRP

GeneTex (26741, Lot 9788061)

Goat

1:5000

Blocking buffer

5% milk in 1% TBST
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CHAPTER 5.
5.1

IDENTIFICATION OF PRL-3 INTERACTOMES IN T-ALL

Introduction

Critical questions remain to be answered in the PRL-3 research field. For
example, PRL-3’s substrates and its exact molecular mechanisms involved in cancer
progression and relapse are largely unknown70. The weak and transient interactions
between PRL-3 and its substrates due to its extremely wide and shallow catalytic pocket47
makes the isolation of PRL-3 complexed with its substrate really difficult. This challenge
is reflected ty the lack of reports on PRL-3 substrates. Only keratin 875and integrin β177
have shown evidence as PRL-3 direct substrates in the literature. The phosphorylation of
keratin 8 and integrin β1 was regulated by PRL-3 overexpression or knockdown. More
importantly, the direct interaction between PRL-3 and keratin 8 or integrin β1 was
demonstrated by Co-IP and/or co-localization assays. A few other PRL-3 interacting
proteins, not necessarily direct targets, have been reported (Table 2). It seems that PRL-3
substrates are cancer type dependent and no PRL-3 substrates in leukemia have been
reported. As discussed in Chapter 4, Src pathway is regulated by PRL-3 via dephosphorylation at tyrosine 527 in T-ALL. However, Src is not a direct substrate of PRL3. The identification of PRL-3 substrates in T-ALL would be helpful to understand the
mechanism of how PRL-3 contribute to tumor progression and migration.
In order to study PRL-3 substrates in T-ALL, a BioID-based proximity labeling
approach (Figure 23A) was used to characterize PRL-3 interacting proteins to start with.
The advantages of this approach over other traditional methods to study interactomes is
in that it can be used to identify the proteins that weakly or transiently interact with the
protein of interest and is also effective to study insoluble, inaccessible, or low-abundant
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interacting protein139. Briefly, BioID2, a biotin ligase, is fused to PRL-3 protein and
overexpressed in cells, where BioID2 biotinylates interacting/adjacent proteins (Figure
23B). As biotinylation is a rare protein modification, biotin modified proteins in this
experiment are candidates for interacting proteins with PRL-3. Then a biotin-affinity
capture method can be used to pull down the biotin-labeled proteins and mass
spectrometry will be used to identify these proteins.
5.2
5.2.1

Materials and Methods
Antibodies, DNA Plasmids and Other Reagents

Antibodies used in this study, including their manufacturer, catalog number, lot
number, blocking buffer used, and dilution factor are listed in Table 8.
Lentiviral packaging plasmids psPAX2 (Addgene 12260, Watertown, MA, USA)
and pMD2.G (Addgene 12259) were from Didier Trono, pLenti PGK Puro DEST (w5292, hereafter referred to as PGK) (Addgene 19068) and pLenti PGK GFP puro (w509-5,
hereafter referred to PGK:GFP) (Addgene 19070) were from Eric Campeau & Paul
Kaufman. MCS-BioID2-HA (Addgene 74224) was from Kyle Roux. QuikChange
Lightning Site-Directed Mutagenesis Kit was from Agilent (210518).
pENTR: BioID2-HA-PRL-3 Gateway Entry construct was made from Gibson
assembly, where BioID2-HA was PCR amplified from MCS-BioID2-HA with a
homologous overhang to NcoI linearized pENTR: PRL-3 and pENTR: PRL-3 was
digested with NcoI. The PGK: BioID2-HA-PRL-3 was generated using the PGK
destination vector and pENTR: BioID2-HA-PRL-3. PGK: BioID2-HA was generated by
introducing an out-of-frame insertion in the PRL-3 domain in PGK: BioID2-HA-PRL-3 to
disrupt PRL-3 translation using a QuikChange Lightning Site‑ Directed Mutagenesis kit.
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PGK: 3×Flag PRL-3 Wt was generated by LR cloning using pENTR: 3×Flag
PRL-3 and PGK destination vector, according to manufacturer’s protocol (ThermoFisher
11791020). PGK:3×Flag PRL-3 C104S was generated using QuikChange Lightning
Site‑ Directed Mutagenesis kit.
The buffers and reagents used in Biotinylated protein pulldown are listed in Table
9.
5.2.2

T-ALL Cell Lines and Cell Culture

The human T-ALL cell lines used in the study were authenticated by short tandem
repeat (STR) DNA profiling and tested for mycoplasma contamination prior to
experimentation. Cells were grown in RPMI1640 (ThermoFisher 11875119)
supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals,
S11150H, Lot M17161, Flowery Branch, GA, USA). Cells were at 37°C in a humidified
atmosphere with 5% CO2.
5.2.3

Lentivirus Packaging and T-ALL Cells Infection

Lentivirus was produced in 293T cells using TransIT-LT1 (Mirus Bio MR2300,
Madison, WI, USA), according to the manufacturer’s instructions using PGK:BioID2-HA
or PGK: BioID2-HA-PRL-3. To generate cell lines that overexpress baits, 2.5mL virus
with 10μg/mL polybrene (Thermo Fisher Scientific TR-1003-G) was added to 5x105 cells
and centrifuged at 2250 rpm for 90 minutes. Virus was washed out with PBS after 24h,
and cells were selected in culture media with puromycin (5μg/mL for Jurkat cells and
2μg/mL for HBP-ALL cells) produce stable cell lines, then maintained in media with
puromycin thereafter.
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5.2.4

Biotinylated Protein Immunoprecipitation

For small scale biotinylated protein immunoprecipitation, cells were incubated
with 50 μM biotin for 16 h prior to harvesting. About 30 million cells were collected and
washed in cold PBS twice, then cells were lysed in 1ml Pierce RIPA buffer (Thermo
Scientific 89900) supplemented with protease inhibitor at 4°C with shaking for 30
minutes. The supernatant was collected and incubated with 200 μL of Dynabeads
overnight. Beads were collected using a magnetic stand and washed three times with cold
PBS. Then the beads-protein complex was boiled in 50 μL SDS containing buffer to elute
the biotinylated protein from the beads. Total protein and eluted biotinylated protein were
used for western blot analysis.
Large scale biotinylated protein pulldown was performed by the Proteomics
Shared Resources at Sanford Burnham Prebys as previously described140. Briefly, prior to
harvesting, cells were incubated with 50 μM biotin for 16 h. 100 million cells were
collected and washed in cold PBS twice, then cells were lysed in 2.4 ml of cell lysis
buffer with two times of sonication, each for 1 min at 30% duty cycle and an output level
of 4 (Sonifer-250; Branson). 2.4 ml of 50 mM Tris (pH 7.4) as added to the cell lysate
and spun at 16,500 × g for 10 min. The supernatant was collected to a 15-ml conical tube
and incubated with 300 μL of Dynabeads overnight. Beads were collected using a
magnetic stand and washed twice with wash buffer 1, once with wash buffer 2, once with
wash buffer 3 and once in buffer 4. Finally, beads-biotinylated protein complex was used
for mass spectrometry analysis.
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5.2.5

Mass Spectrometry and Data Analysis

Mass spectrometry analysis and analysis was performed by the Proteomics Shared
Resources facility at Sanford Burnham Prebys as previously described139. Briefly, beadsbiotinylated protein complexes captured in 4.2.4 were resuspended in 50 μL of 8 M
urea/50 mM ammonium bicarbonate and 2 μL of 0.5 M Tris (2-carboxyethyl) phosphine
was added to the suspension, then incubated for 60 min at 30°C to reduce the protein.
After cooling down the reaction, 4 μL of 0.5 M iodoacetamide was added for alkylation
at room temperature in the dark for 30 min. 350 μL of 50 mM ammonium bicarbonate
was added to the reaction to dilute the 8 M urea to 1 M prior to trypsin digestion.
Overnight digestion was performed at 30° with shaking at 700 rpm by adding 5 μg of
MS-grade trypsin (Promega, Madison, WI) to the protein-bead complexes. Digested
peptides were isolated from the beads by centrifugation and magnetic separation, then
transferred to a new tube. The beads were washed in 50 μL of 50 mM ammonium
bicarbonate to collect peptide residues, which were pooled with the previous peptide
solution. Formic acid was added to the peptide solution (final concentration 2%), which
was then desalted by using Microtrap (77720; Thermo Scientific, Waltham, MA).
Finally, 10% of total peptides in duplicate runs were performed using a high-resolution,
high-accuracy LC-MS/MS system , which includes an EASY-nLC 1000 HPLC, Acclaim
PepMap peptide trap, 25 cm × 2 μm Easy-Spray C18 column, Easy Spray Source, and Q
Exactive Plus mass spectrometer (all from Thermo Fisher Scientific).
The LC-MS/MS raw data of three technical replicates were combined and
submitted to Sorcerer Enterprise, version 3.5 (Sage-N Research, Milpitas, CA) with
SEQUEST algorithm as the search program for peptide/protein identification. SEQUEST
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was set up to search the target-decoy EBI.IPI.HUAMAN (version 3.73) protein database
containing protein sequences, using trypsin for enzyme with an allowance of up to two
missed cleavages, Semi Tryptic search, fixed modification of 57 Da for cysteine to
account for carboxyamidomethylation, and precursor mass tolerance of 50 ppm.
Differential search includes 16 Da for methionine oxidation and 226 on lysine for
biotinylation. The search results were viewed, sorted, filtered, and statistically analyzed
by using comprehensive proteomics data analysis software Peptide/Protein prophet,
version 4.02 (ISB). The minimum transproteomic pipeline (TPP) probability score for
proteins was set to 0.9 to assure very low error (much less than a false discovery rate of
2%) with reasonably good sensitivity. The differential spectral count analysis was done
by QTools, an open-source in-house–developed tool for automated differential
peptide/protein spectral count analysis. Proteins with fewer than three spectral counts or
common MS background proteins, including keratins, histones, and ribosomal proteins,
were removed due to the lack of confidence. Any candidate identified by BioID2-PRL-3
was excluded if the relative percentage of total spectral counts was threefold less than in
the BioID2-only.
5.2.6

Western Blot

Western blot analysis was performed using a stain-free technology developed by
BioRad, which allows for the use of total protein as the loading control121. For all figures
shown, a band of total protein ~50kD is size is used to represent the lane of total protein.
An example es shown in Figure 3B.
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5.2.7

Co-immunoprecipitation

Cells (~50 million) were lysed in Pierce IP lysis buffer (Thermo 87788)
supplemented with 1% Protease Inhibitor Cocktail (Sigma P8465). Total protein was
incubated with 80 μL Anti-Flag M2 magnetic beads (Sigma m8823) on shaker overnight.
After removing supernatant and washing the beads with PBS gently, the magnetic beads
were boiled with 50 μL SDS containing buffer to elute the immunoprecipitants from the
beads. Total cell lysates and immunoprecipitants were used for western blot analysis.
5.2.8

Statistical Analysis

Fisher’s Exact test was performed in PANTHER Overrepresentation Test.
5.3
5.3.1

Results
BioID2 Expression Led to Biotinylation of Proteins in T-ALL

In order to use BioID2-based proximal labeling to study PRL-3 interacting
proteins in T-ALL, we overexpressed fusion proteins BioID2-PRL-3 or BioID2 in two TALL cell lines, HSB2 and Jurkat. Overexpression of BioID2 in HSB2 or Jurkat cells
(hereafter referred as HB/JB) and BioID2-PRL-3 in HSB2 or Jurkat cells (hereafeter
referred as HBP/JBP) was validated by western blot analysis (Figure 24A). As shown in
Figure 24B, incubation of HB/JB or HBP/JBP cells in biotin rich medium led to global
biotinylation of proteins.
5.3.2

Identification of PRL-3 Proximal Proteins

A large scale Strep-avidin pulldown followed by mass spectrometry was
performed to identify PRL-3 interacting proteins. Duplicates of 10 × 107 BioID2-PRL-3
cells or BioID2 cells (control), processed in parallel, were analyzed for the experiment.
The cells were incubated in Biotin-rich medium (50 μM) for 16hrs prior to cell lysis for
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total protein. Biotinylated proteins were pulled down by streptavidin magnetic beads,
rigorously washed and analyzed by mass spectrometry. Large amounts of diverse proteins
(~3000) were identified by mass spectrometry.
It is challenging to determine which protein represent bona fide PRL-3 interactors
versus those that are background contaminants or proximal proteins but not really
interacting with PRL-3. As background contaminants are mostly bait-independent, the
proteomics community collected proteins presents in the negative controls from large
amounts of the affinity purification- mass spectrometry (AP-MS) studies to generate an
open data base, Contaminant Repository for Affinity Purification (the CRAPome)119. The
CRAPome was used to score the proteins identified in the BioID2-MS experiment and
only the proteins with CRAPome <0.5, which represents the protein present in <50% APMS studies and less likely to be contaminants, were used for the next step analysis.
As proteins that interact with PRL-3 should have higher level of biotinylation in
BioID2-PRL-3 cells compared with that in BioID2 only cells, the fold-change of
biotinylated proteins in BioID2-PRL-3 cells versus BioID2 cells was plotted (Figure
24A), which showed four distinct clusters: Cluster A represents the proteins that showed
Log2 Foldchange >3.3 of biotinylation in JBP cells but not in HBP cells versus their
respective controls. Cluster B represents the proteins that showed Log2 Foldchange >3.3
fold-change in both HBP and JBP cells. Most of the proteins in Cluster B showed the
CRAPome score equal to 0 ( green dots in Figure 24A), suggesting these are unique
proteins captured by this BioID2-MS approach. Cluster C represents the proteins that
showed Log2 Flodchange <3.3 of biotinylation in both HBP and JBP cells. Cluster D
represents the proteins that showed Log2 Flodchange >3.3 of biotinylation in HBP cells
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but not in JBP cells. The two previously reported PRL-3 interacting proteins, CNNM3
(Log 2 Foldchange = 9.75 in HBP and Log 2 Foldchange = 9.44 in JBP) and CNNM4
(Log 2 Foldchange = 8.57 in HBP and Log 2 Foldchange = 9.21 in JBP), were found in
cluster b. PRL-3 protein itself also showed high level of biotinylation (Log2 Foldchange
= 11.16 in HBP and Log2 Foldchange = 11.53 in JBP).
In order to identify PRL-3 direct interacting proteins in T-ALL, we first analyzed
proteins in cluste B, 288 common biotinylated proteins in both HBP and JBP, using
PANTHER Overrepresentation Test ( Figure 25B). The PANTHER Overepresentation
Test revealed the top 8 pathways that those common biotinylated proteins are enriched in,
including α-adrenergic receptor signaling pathway, T cell activation, 5HT2 type receptor
mediated signaling pathway, oxytocin receptor mediated signaling pathway, B cell
activtaiton, thyrotropin-releasing hormone receptor signaling pathway, PDGF signaling
pathway and endothelin singliang pathway.
5.3.3

Validation of Biotinylated Proteins

Identification of protein interactomes using AP-MS normally produces high rates
of false positives. Although CRAPome scoring was used previously in the study to
exclude most background contaminants, which are generally introduced at the
purification stage, the false positives could also be generated by tandem MS step, such as
misidentified by database searching algorithms. Therefore, validation of the interacting
proteins identified by MS is important. Based on the PANTHER analysis and biological
significance of the proteins in T-ALL, we decided to examine the biotinylation status of
top hits LCK (lymphocyte-specific protein tyrosine kinase), CD3ε (cluster of
differentiation 3 T cell co-receptor ε subunit), Notch1, Rictor (Rapamycin-insensitive
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companion of mammalian target of rapamycin), LAT (Linker for activation of T cells)
and CXCR4 (C-X-C chemokine receptor type 4) in JBP and JB cells using streptavidin
pulldown followed by western blot analysis. JB and JBP cells were cultured in biotin rich
medium (50 μM) for 16 hours prior to harvesting and then total protein was extracted for
streptavidin pulldown assay. After rigorous washing, the biotinylated proteins bound to
the streptavidin magnetic beads were denatured, released from the beads when subject to
boiling in buffer containing beta mercaptoethanol and probed using western blot analysis
(Figure 26A). We found that LAT and CXCR4 were not biotinylated in JB or JBP cells,
biotinylated Notch 1 is found at a higher level in JB cells compared to JBP cells,
suggesting non-specific biotinylation. These hits were excluded from further analysis.
Biotinylation of LCK, CD3ε and Rictor was significantly higher in JBP cells compared to
JB cells, suggesting that LCK, CD3ε and Rictor are potential PRL-3 interacting proteins.
5.3.4

Identification of Direct Interacting Protein of PRL-3

As BioID2-PRL-3 biotinylates all the proximal proteins of PRL-3, the
biotinylated LCK, CD3ε, and Rictor identified by streptavidin pulldown and MS are not
necessarily proteins that directly interact with PRL-3, but instead may be in close
proximity. In order to examine whether LCK, CD3ε, Notch I and Rictor directly interact
with PRL-3 or not, we generated Jurkat cells that express 3×Flag PRL-3 Wt, 3×Flag
PRL-3 C104S, which is a catalytic inactive and substrate trapping PRL-3 mutant48, and
Jurkat GFP control cells for co-immunoprecipitation assay. As shown in Figure 26B,
anti-Flag magnetic beads pulled down Flag-PRL-3 Wt or C104S together with LCK and
CD3ε but not Rictor
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In order to know whether the formation of PRL-3: LCK: CD3ε complex is
dependent on PRL-3 phosphatase activity, we next performed the same co-IP assay with
or without the presence of a phosphatase inhibitor, vanadate. The total protein lysate of
Jurkat GFP or 3×Flag PRL-3 Wt or 3×Flag PRL-3 C104S were split into two different
tubes, one with and one without vanadate (2 mM) treatment followed by incubation at 4°
C with shaking for 1h. Then, anti-Flag magnetic beads were added to the cell lysate with
or without vanadate to pull down 3×Flag PRL-3 or C104S together with their binding
proteins. As shown in Figure 26C, the addition of vanadate to the cell lysate did not
disrupt the PRL-3: LCK: CD3ε complex, suggesting the formation of the complex is not
dependent on PRL-3’s phosphatase activity.
5.4

Discussion

PRL-3 substrates are largely unknown, and although PRl-3 was found to modulate
Src signaling to promote migration in T-ALL, the direct substrate of PRL-3 has not been
found in T-ALL. Here we used a BioID2-based proximal labeling approach followed by
MS to identify a pool of PRL-3 interacting proteins. Subsequent western blot validation
of biotinylated proteins identified by MS demonstrated that a high percentage of PRL-3
proximal proteins captured by BioID2 proximal labeling are actually biotinylated,
suggesting that BioID2 approach to study PRL-3 interacting proteins is feasible and
provides hints for substrate exploration and discovery. The co-IP assay revealed a 3protein complex, PRL-3: LCK: CD3ε, suggesting that PRL-3 is physically associated
with LCK and/or CD3ε, both of which are critical components of T cell receptor (TCR)
signaling. In the canonical TCR signaling model, a critical step is that LCK/Fyn (Src
family tyrosine-protein kinase) phosphorylates immunoreceptor tyrosine-based activation
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motif (ITAM) on CD3, which then serve as docking site for another tyrosine kinase ZAP70. ZAP-70 is also activated by LCK via phosphorylation, then continues to
phosphorylate LAT, an adaptor protein, which further recruits downstream signaling
molecules, including Slp76, phospholipase C1, Grb2, and GADS, resulting in T-cell
activation141,142. LCK hyperactivation was associated with glucocorticoid resistance in
pediatric T-ALL patients and chemical inhibition or genetic knockdown of LCK was able
to reverse glucocorticoid resistance in T-ALL cell lines and patient-derived xenografts
(PDX) cells. One of the mechanisms that LCK mediates GC resistance is via
calcineurin/NFAT pathway that leads to the upregulation of IL-4143. LCK hyperactivation
was also found in early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL),
which is critical for T-cell leukemogenesis144.
Our co-IP study found that PRL-3 and LCK were in the same protein complex. It
is possible that PRL-3 can modulate LCK activity via de-phosphorylation. Another
possibility is that PRL-3 acts as a scaffold protein that brings LCK and CD3 together and
modulates LCK/TCR signaling pathway. We need to further determine that whether CD3
or LCK is directly associated with PRL-3 and how PRL-3 modulate LCK/TCR signaling
pathway.
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Figure 23. Schematic of BioID2 Proximal Labeling to Identify PRL-3 Interactomes.
(A)Principal of BioID2 proximal labeling. BioID2, a biotin ligase, is fused to your
interest of protein to generate the bait protein. When the bait protein is expressed in the
cells, the proximal proteins around the bait protein will be biotinylated, captured by
affinity purification, and their identify can be determined by MS. (B) Expression of
BioID2-PRL-3 fusion protein in T-ALL cells, Jurkat and HSB2, leads to the selective
biotinylation of proteins proximate to PRL-3. Biotinylated proteins are purified by Strepavidin beads and can be identified by mass spectrometry.
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Figure 24. Expression of BioID2-PRL-3 Led to Biotinylation of Proteins.
(A) Expression of BioID2-PRL-3 or BioID2 was detected HSB2 and Jurkat cell lines that
were transfected with lentivirus followed by puromycin selection. (B) Incubation of
HSB2 and Jurkat cells that overexpress BioID2 or BioID2-PRL-3 in biotin rich medium
(50μM) for 16 hours led to biotinylation of proteins. HB, HSB2-BioID2; HBP, HSB2BioID2-PRL-3; JB, Jurkat-BioID2; JBP, Jurkat-BioID2-PRL-3.
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Figure 25. Identification of Biotinylated Proteins in BioID2-PRL-3 or BioID2.
(A)The biotinylated proteins were pulled down by streptavidin magnetic beads and
identified by mass spectrometry. Proteins with a CRAPome score >0.5131, which are
likely to be contaminants, were excluded. CNNM481 and CNNM391 were previously
reported as direct interacting protein of PRL-3. The color represents different CRAPome
score (0-0.49) and size of the dot represents unique peptides identified by MS. (B) 288
common biotinylated protein that were present in both HBP and JBP and Log2
Foldchange >3.3 folds with unique peptides>3 were selected for PANTHER
Overrepresentation Test (PANTHER 14.1), which showed top 8 pathways enriched in
cells that express BioID2-PRL-3 protein.
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Figure 26. Identification of PRL-3 Interacting Proteins.
(A) Representative figure showed biotinylated LCK or CD3ε or Rictor were enriched by
streptavidin pulldown in Jurkat-BioID2-PRL-3 (JBP) cells compared with Jurkat-BioID2
(JB) cells, which were cultured in biotin-rich medium prior to pulldown. (B) Co-IP by
anti-Flag using Jurkat 3×Flag PRL-3 Wt or Jurkat 3×Flag PRL-3 C104S or Jurkat GFP
(control) cells showed a PRL-3: LCK: CD3 complex. The figure is a representative figure
of n=3 (C) The presence of vanadate (2mM) in the total protein of Jurkat 3×Flag PRL-3
Wt or Jurkat 3×Flag PRL-3 C104S cells for Co-IP did not disrupt the formation of a
PRL-3: LCK: CD3 complex. The figure is a representative figure of n=3.
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Table 8 List of Antibodies, Their source and Working dilutions
Reagents
Source
Host
species
Streptavidin-HRP
Cell Signaling (3999S, Lot 7)
/
Anti-BioID2

Working
dilution
1:1000

Chicken 1:10000

Anti-LCK

BioFronTech (BID2-CP-100,
Lot 03290116)
Cell Signaling (6943, Lot 4)

Rabbit

1:1000

Anti-LCK_pY505

Cell Signaling (2751, Lot 7)

Rabbit

1:1000

Anti-LCK_pY394

Genetex (GTX133876, Lot 42935

Rabbit

1:1000

Anti-CD3 ε

Cell Signaling (2105, Lot 9)

Rabbit

1:1000

Anti-Rictor

Cell Signaling (21147, Lot 7)

Rabbit

1:1000

Anti-Notch1

Cell Signaling (3608, Lot 8)

Rabbit

1:1000

Anti- LAT

Cell Signaling (45533, Lot 1)

Rabbit

1:1000

Anti-CXCR4

Abcam (ab124824, Lot GR3231217-6)

Rabbit

1:1000

Anti-Flag M2

Sigma (F1804, Lot SLBK1346V)

Mouse

1:1000

Anti-Flag M2

Cell Signaling (14793, Lot 5)

Rabbit

1:1000

Mouse IgG-HRP

Cell Signaling (7106, Lot TC2625)

Goat

1:5000

Rabbit IgG-HRP

Genetex (26741, Lot 9788061)

Goat

1:5000

Chicken IgY-HRP

Abcam (ab97135, Lot GR320991-9)

Goat

1:10000

Blocking buffer

5% milk in 1% TBST

/

/

Blocking buffer

5% BSA in 1% TBST

/

/
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Table 9 Reagents and Buffers for BioID2 Pulldown Assay
Name
Halt Phosphatase Inhibitor Cocktail

Source or formula
Life Technologies

Dynabeads™ MyOne™
Streptavidin C1

R&D (MAB32191, Lot XJS01)

Cell lysis buffer

50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS,
1 mM dithiothreitol, and 1× protease inhibitor

Wash buffer 1

2% (wt./vol) SDS

Wash buffer 3

0.1% deoxycholate, 1% Triton X-100, 500 mM
NaCl, 1 mM EDTA, and 50 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid,
pH 7.5
250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate,
1 mM EDTA, and 10 mM Tris, pH 8

Wash buffer 4

50 mM Tris, pH7.4

Wash buffer 2
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CHAPTER 6.
6.1

FINAL CONCLUSIONS AND FUTURE DIRECTION

Final Conclusion

The overall goal of this dissertation is to understand the role of the protein
tyrosine phosphatase PRL-3 in T-ALL progression and explore the potential of PRL-3 as
therapeutic target for T-ALL. The results presented in this dissertation showed that PRL3 is highly expressed at both the mRNA level and protein level in T-ALL patients. PRL-3
shows minimal effect on T-ALL survival and proliferation but contributes to cell
migration capability, which enhances T-ALL progression and circulation in both
transgenic zebrafish and xenotransplantation mice models. We also identified that the Src
signaling pathways is affected by PRL-3 in T-ALL. Although Src is not a direct substrate
of PRL-3, Src_pY527 is indirectly modulated by PRL-3, which is critically involved in
cell migration. In addition, we applied the newly developed BioID2-based proximal
labeling approach to study PRL-3 interactomes and identified a potential PRL-3
substrate, LCK, which also belongs to the Src family and is essential for T-cell
development. More importantly, our study showed that PRL-3 inhibition using a small
molecule inhibitor, JMS-053, did inhibit T-ALL viability and migration, demonstrating
that PRL-3 is targetable in T-ALL. According to our knowledge, this is the first study to
demonstrate the oncogenic role of PRL-3 in T-ALL.
6.2

Future Directions

This is the first study to show that PRL-3 facilitates T-ALL progression and
circulation. PRL-3 is under-explored in T-ALL and there is very limited information of
possible genetic alterations of PRL-3 in T-ALL or other types of leukemia although there
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is evidence that PRL-3 is highly expressed in T-ALL patient samples compared to that in
normal control. Therefore, we need to profile PRL-3 status in T-ALL patient in order to
understand its prevalence and importance in T-ALL. One of the mechanisms behind the
oncogenic role of PRL-3 is via the Src signaling pathway, probably via direct interaction
with LCK and/or CD3, the exact pathway by which PRL-3 affects the Src pathway is still
unknown. In addition, we cannot exclude other pathways affected by PRL-3, which
might also contribute T-ALL initiation and PRL-3. In order to answer these questions,
further investigation is necessary to explore the direct substrate(s) of PRL-3. The BioID2
approach identified a large pool of PRL-3 interacting proteins, which can serve as starting
point for validation of PRL-3 direct substrates. However, it is not practical to validate all
the interactomes of PRL-3 using the conventional co-IP or western blot analysis due to
the large number of PRL-3 interactomes. In order to resolve this issue, high throughput
approaches, such as unbiased proteomics, can be used to identify differential
phosphorylation of LCK or CD3 upon PRL-3 inhibition or overexpression in cell line.
The proteins that can be both biotinylated by BioID2-PRL-3 and their phosphorylation
level is affected by PRL-3 are promising candidates for PRL-3 substrates.
In our study, we found a PRL-3: LCK:CD3 complex using a BioID2 approach
combined with co-IP assay. Whether PRL-3 directly interacts with LCK or CD3 remains
unknown. Structural approaches, such as crystallography and cross-linking MS are
currently being performed to determine the spatial relationship of the protein complex.
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